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Online and Off-Label: Closing the Regulatory
Gap in Online Direct-to-Consumer Drug
Promotion and Prescribing
KRISTINA L. BITZER 1
The advent of telemedicine led to an evolution in healthcare delivery,
making it possible for healthcare professionals to provide remote patient
care, thus minimizing or eliminating the need for the patient to visit a physician’s office. Recently, online telemedicine has gained significant popularity, especially in light of the COVID-19 pandemic. This Comment focuses upon online direct-to-consumer telemedicine platforms and their modern
usage as one-stop-shops for acquisition of medical advice and medication.
Specifically, this Comment explores prescription promotion and prescribing
as done through these platforms with a special examination of off-label
prescriptions. Several modern online direct-to-consumer telemedicine platforms offer prescription medications directly to the patients who visit their
websites. The platforms advertise these prescriptions on both their individual websites as well as through social media. Some of the medications offered and promoted by these platforms are not FDA approved for the conditions that they are advertised to treat. This Comment explores regulations
and liability considerations surrounding prescription advertising and prescribing, specifically as they relate to online direct-to-consumer telemedicine platforms. Because these platforms claim to be neither medical providers, pharmaceutical companies, nor online pharmacies, they fall into a regulatory gap. This Comment concludes by suggesting that federal legislation
or regulations should be promulgated accordingly to bridge this gap, particularly given increased dependence upon these platforms in light of the
COVID-19 pandemic.
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I.

INTRODUCTION

Picture yourself as a young professional during the height of the
COVID-19 pandemic circa Spring 2020.2 Quarantines and shutdowns are
occurring nationwide, hospitals are rapidly filling up with patients on ventilators, and American health and governmental authorities instruct you to
only leave your home for essentials. You have been working online at your
corporate job where operations have continued somewhat normally, albeit
remotely. However, there have been layoffs due to the virus’s impact on the
economy and you want to do everything in your power to avoid being the
next person on human resources’ hit list. You have a big presentation coming up for work and you really want to nail it, but you know that you experience severe anxiety with public speaking and it hinders your performance.
2. See generally A Timeline of COVID-19 Developments in 2020, AM. J. M ANAGED
CARE (Jan. 1, 2021), https://www.ajmc.com/view/a-timeline-of-covid19-developments-in2020 [https://perma.cc/38WG-7VZR].
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The thought of doing a presentation in an online format is even more nerveracking. What if your spotty internet fails? What if an Amazon delivery
comes and the dog starts barking? You’re freaking out.
You realize that everything has been quite overwhelming and you consider finding a doctor to prescribe some anti-anxiety medication prior to
your big presentation. However, the shutdowns are making it difficult to
schedule an appointment and, even if you could get in to see someone, you
would be afraid to leave the house. One night you’re scrolling through Instagram when you see an ad for a website called Hers.3 This website has a
bunch of different prescriptions available for multiple mental health conditions, including a medication called Propranolol which is listed under the
heading of “performance anxiety.”4 You do a quick online search and also
find a website called Kick5 which specifically gears its offerings towards
people with your exact problem.6 This site also offers this Propranolol medication7 which people take before big presentations, exams, or other stressful situations.8 This sounds like a perfect solution. Moreover, you can obtain medication on the internet without leaving your house—all you have to
do is go online, answer some questions, and have a short virtual consultation with a medical professional.9 They’ll send the medication right to your
home. 10 You’re determined to get this drug, and get it fast. Presentation day
will be here before you know it.
Direct-to-consumer (DTC) telemedicine websites like Hers and Kick
rapidly made their way into the mainstream prior to COVID-19, but the
pandemic afforded them an opportunity to demonstrate their value.11 These
3. Hers for Women’s Health, HERS, www.forhers.com [https://perma.cc/46EQ8GQU].
4. Propranolol,
H ERS,
https://www.forhers.com/well-being/propranolol
[https://perma.cc/4RCC-BD3X]; see also Jessica Defino, The Dangerous Side Effect of
Digital Wellness, F ASHIONISTA (Mar. 20, 2019), https://fashionista.com/2019/03/digitalhealth-wellness-companies-government-regulations [https://perma.cc/4PGM-TR43].
5. Kick: Insider’s Edge to the Best You, KICK, https://www.gokick.com
[https://perma.cc/ZPR5-K6WE].
6. See generally Kristen V. Brown & Gerrit De Vynck, Startups Are Hawking
Zoloft and Beta Blockers for Off-Label Uses, BLOOMBERG Q UINT (Apr. 4, 2019, 12:57 AM),
https://www.bloombergquint.com/business/startups-are-hawking-zoloft-and-beta-blockersfor-off-label-uses [https://perma.cc/9LN3-MAYP].
7. Feeling Anxious? Propranolol Can Calm Your Body and Ease Your Nerves,
KICK, https://www.gokick.com/guides/anxiety/propranolol/ [https://perma.cc/TRC3-NZKS].
8. Id.
9. See generally Yasmin Gagne & Burt Helm, Buying Prescription Drugs Online
is Easier Than Ever. But There Are Side Effects, FAST CO. (Sept. 11, 2019),
https://www.fastcompany.com/90396205/buying-prescription-drugs-online-is-easier-thanever-but-there-are-side-effects [https://perma.cc/J3XQ-Z53T].
10. See generally id.
11. TARA J AIN & ATEEV M EHROTRA, COMPARISON OF D IRECT-TO-CONSUMER
TELEMEDICINE
V ISITS
WITH
PRIMARY
C ARE
VISITS,
1
(2020),

2021]

ONLINE AND OFF-L ABEL

167

sites use direct-to-consumer marketing paired with telemedicine technology
to serve as convenient, one-stop shops for patients looking to receive treatment for common conditions from the comfort and safety of their own
homes.12 Through these websites, patients can leisurely browse treatments
and medications for conditions ranging from migraines,13 to skincare,14 to
sexual performance,15 and beyond.16 Some websites even allow patients to
add the medication to their electronic shopping carts, pay for it, enter shipping information, and have the drug’s appropriateness evaluated by a provider following payment in order to streamline the process. 17
These sites appeal to the modern consumer because they are convenient, discreet, and efficient. While the benefits of such a healthcare delivery
system are plentiful, especially in the midst of a pandemic, use of this model presents some inherent dangers.18 Patients often have pre-conceived notions of what medications are right for them based on self-diagnosis19 or
arbitrary internet searches, and direct access to those medications via online
platforms removes the initial independent judgment of a medical professional.20 The model does not allow for a medical professional to perform an
in-person, visual examination of the patient nor take important vitals, like
blood pressure and heart rate, that are often prerequisite to determining
whether a medication is appropriate for a patient.21 Of further concern is the
fact that several medications available through these online DTC medicine
platforms are being advertised and prescribed for “off-label,” non-FDA
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2773813
[https://perma.cc/NL7G-EMRY].
12. See generally Gagne & Helm, supra note 9.
13. See,
e.g.,
Best
Medication
for
Migraine
Headaches,
COVE,
https://www.withcove.com/our-offering [https://perma.cc/NG68-3T8T].
14. See, e.g., Apostrophe: Acne Treatment That Delivers, APOSTROPHE,
https://www.apostrophe.com [https://perma.cc/NW8M-T6B5].
15. See,
e.g.,
Sertraline
for
Premature
Ejaculation,
HIMS,
https://www.forhims.com/drug/sertraline-for-pe [https://perma.cc/LD8U-EPQY].
16. Gagne & Helm, supra note 9 (“San Francisco–based Lemonaid Health, founded
in 2013 and forerunner [in DTC online medicine], now sells medication for more than a
dozen different conditions . . . .”).
17. See,
e.g.,
Zolmitriptan:
Immediate
Migraine
Relief,
COVE,
https://www.withcove.com/products/zolmitriptan [https://perma.cc/A9VN-8TX6] (demonstrating an example of this process); see also Gagne & Helm, supra note 9 (explaining that
interactions with physicians via DTC medicine platforms often begin after the patient has
added his or her desired prescription medication into an electronic shopping cart).
18. See generally Vishal Khetpal, The Worrisome Rise of Direct-to-Consumer Medicine, UNDARK (Mar. 28, 2019), https://undark.org/2019/03/28/digital-health-dilemma/
[https://perma.cc/FNM6-4SFX].
19. Gagne & Helm, supra note 9.
20. See generally id.; see also Khetpal, supra note 18.
21. See generally id.
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approved uses.22 From a legal standpoint, the advertisement and prescription of these off-label medications by these platforms fall within a regulatory grey area because these websites hold themselves out to be mere communication platforms which connect independent providers with patients. 23
That is, the websites claim that they are not providers of healthcare nor distributors or manufacturers of drugs24—which are subject to unique regulation—and explicitly state as much in their individual Terms and Conditions.25
This Comment explores off-label advertising and prescribing performed through these sites alongside regulatory and liability considerations.
It goes on to analogize these platforms to hospitals which have been historically unsuccessful in claiming that they are mere facilitators of care, simply
providing a space for patients to connect with physicians. 26 The Comment
concludes by suggesting that Congress or a federal regulatory agency
should act to regulate the online DTC medicine platforms specifically in
order to protect both patient safety and to ensure continued integrity of the
medical profession.
II.

TELEMEDICINE IN THE UNITED STATES

Telemedicine, also sometimes referred to as “telehealth,”27 can be defined simply as “the use of telecommunication and information technology
to provide clinical health care from a distance.”28 Telemedicine has been an
22. See Brown & De Vynck, supra note 6.
23. Khetpal, supra note 18.
24. See Gagne & Helm, supra note 9 (explaining how DTC telemedicine companies
seek to “insulate themselves from treatment decisions” by claiming that they are merely
platforms “facilitating interactions between patients and physicians.”).
25. See, e.g., Kick Terms of Use, KICK (Sept. 2018), https://www.gokick.com/terms/
[https://perma.cc/WPW8-HBVR] (“We offer an online communication platform for Providers and their patients to connect via the Site through the use of synchronous and asynchronous telecommunications technologies. The Site facilitates communication between patients
and Providers. Kick does not provide medical advice or care.”); Hims: Terms & Conditions,
HIMS
(Dec.
17,
2020),
https://www.forhims.com/terms-and-conditions
[https://perma.cc/8XFN-T9F6] (“We are a technology company that makes available to
individuals who register as users of the Service (“Users”) certain products and services sold
or offered by Hims or by third-party medical providers, pharmacies, or other vendors. [. . .]
With respect to the Labs, Pharmacies, the Medical Groups and the Providers, we act solely
as a technology platform to connect you with the products and services offered by the Labs,
Pharmacies, Medical Groups and Providers through the Service.”).
26. See infra text accompanying notes 323-54.
27. Alexis S. Gilroy, Digital Health Transactions—An Overview of Unique Considerations for Any Deal Lawyer Working on a Telemedicine, Telehealth, or Health Transaction, 2016 H EALTH L. H ANDBOOK 12 (2016).
28. Hamidreza Shirzadfar & Fatemeh Lotfi, The Evolution and Transformation of
Telemedicine, 3 INT’L J. BIOSENSORS & BIOELECTRONICS 303 (2017).
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invaluable resource for remotely connecting providers and patients for decades.29 The modern concept of telemedicine has its roots as far back as the
early 1900s, when the inventor of the electrocardiogram proposed the use of
the telecardiogram.30 In the 1920s, the radio was used to give medical advice to medical crews on ships. 31 By the 1940s, medical records were able
to be transferred electronically to a location over twenty-four miles away
through use of a telephone line.32 Advancements in telemedicine technology were plentiful during the 1950s through the 1970s with the advent of
teleradiology systems and, soon thereafter, video medicine systems. 33 During this time, the United States government sponsored a telemedicine project that sought to utilize satellite-based communications in order to provide
health services to astronauts in space as well as to Native Americans on a
remote reservation.34
Since then, telemedicine has quickly evolved and grown to meet the
ever-changing needs of patients and providers.35 Hospitals and doctors’
offices use telemedicine services to connect providers to each other, as well
as to patients.36 For example, rural healthcare providers with limited resources may use telemedicine to transmit real-time data and health information to facilities with more expansive capabilities and specialties in order
to provide life-saving treatment.37 Modern telemedicine capabilities are
even used to render remote emergency service through mechanisms such as
mobile stroke units, utilizing remote communication and transmission of
diagnostic imaging to provide time-sensitive treatment.38 Furthermore, telemedicine resources have been crucial in connecting rural and underserved
patients with healthcare services that would otherwise be unavailable to

29. See generally id.
30. Thomas S. Nesbitt, The Evolution of Telehealth: Where Have We Been and
Where Are We Going?, in THE ROLE OF TELEHEALTH IN AN EVOLVING H EALTH CARE
ENVIRONMENT 12 (Tracy A. Lustig ed., 2012).
31. Id.
32. TELEMEDICINE: A GUIDE TO ASSESSING TELECOMMUNICATIONS FOR HEALTH
CARE 36 (Marilyn J. Field ed., 1996).
33. Id. at 36-39.
34. Id. at 39.
35. See generally Nader Amer, Comment, Dr. Tele-Corporation: Bridging the
Access-to-Care Gap, 123 DICK. L. REV. 481, 488-89 (2019).
36. Id.
37. Id.
38. See generally Ketevan Berekashvili, Mobile Stroke Units and Telemedicine for
Delivering Acute Stroke Treatment in Resource Rich and Poor Environments and to Vulnerable
Populations,
3
INTERNAL
M ED.
R EV.,
no.
4,
2017,
at
1,
https://internalmedicinereview.org/index.php/imr/article/viewFile/455/pdf
[https://perma.cc/7XV6-8HW7].
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them.39 For example, there is a shortage of both psychiatrists and dedicated
mental health treatment centers in the United States. 40 Telemedicine has
made it possible for psychiatrists to provide both care and prescription access to patients that may otherwise be forced to go without.41 Providers in
multiple specialties can perform either telephonic or video-based visits with
patients that may otherwise forgo treatment due to lack of area resources,
mobility impairments, or difficulty finding time to travel to and from physicians’ offices.42 Telemedicine services are typically categorized as either
synchronous—that is, occurring in real time, often via telephone or face-toface—or asynchronous,43 sometimes also referred to as “store-andforward,”44 often facilitated through online questionnaires.
While telemedicine has long played an important role in providing vital medical services to hard-to-reach patients, the COVID-19 pandemic
demonstrated telemedicine’s value more than ever.45 As the COVID-19
virus continued to spread in early 2020, many patients were afraid to enter
doctors’ offices or hospitals for fear that they would contract the virus or
carry it home to a loved one.46 Medical offices operated on limited hours
39. See generally American Telemedicine Association, Direct to Consumer (DTC)
Asynchronous Telemedicine: Improving Access and Empowering Patients, FOLEY &
LARDNER,
https://www.foley.com/-/media/files/insights/health-care-law-today/dtcasync_final.pdf?la=en [https://perma.cc/4BSJ-4ZEP] (explaining how telemedicine bridges
health care access gaps in rural and underserved communities).
40. See generally Robert Caudill, Update on Developments with Ryan Haight and
Online
Prescribing,
AM.
PSYCHIATRIC
ASS’N
(Mar.
22,
2018),
https://www.psychiatry.org/psychiatrists/practice/telepsychiatry/blog/update-ondevelopments-with-ryan-haight-and-online-prescribing [https://perma.cc/9W84-QRJQ].
41. Id.
42. Amer, supra note 35, at 490-93.
43. American Telemedicine Association, supra note 39. “[The American Telemedicine Association] defines asynchronous as a non-real time, technology- assisted exchange of
structured information between a patient and provider with the intent to diagnosis, treat
and/or triage.” Id.
44. Gilroy, supra note 27.
45. See generally Matthew Gavidia, Telehealth During COVID-19: How Hospitals,
Healthcare Providers Are Optimizing Virtual Care, AJMC (Mar. 13, 2020),
https://www.ajmc.com/view/telehealth-during-covid19-how-hospitals-healthcare-providersare-optimizing-virtual-care [https://perma.cc/45M3-AG8J].
46. Mark É . Czeisler et al., Delay or Avoidance of Medical Care Because of
COVID-19–Related Concerns, 69 MWWR: U.S. DEP’T HEALTH & H UMAN S ERVS. 1250
(2020),
https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6936a4-H.pdf
[https://perma.cc/65A5-7WFQ] (“Overall, an estimated 40.9% of U.S. adults have avoided
medical care during the pandemic because of concerns about COVID-19, including 12.0%
who avoided urgent or emergency care and 31.5% who avoided routine care.”); see also
John M. Glionna, Health Crisis Looming Inside a Health Crisis: People Are Avoiding Going
to
the
Doctor,
L.A.
TIMES
(July
29,
2020,
5:00
AM),
https://www.latimes.com/california/story/2020-07-29/coronavirus-people-avoid-visits-todoctor [https://perma.cc/ET62-EEBQ].

2021]

ONLINE AND OFF-L ABEL

171

and reduced staff so as to comply with social distancing recommendations,
and hospitals faced staff and budget reductions. 47 As patients weighed the
benefits of obtaining medical treatment against the risks of contracting the
virus, telemedicine quickly became an unsung hero of the COVID-19 pandemic.48 In the first quarter of 2020 alone, the number of telemedicine visits
increased by 50 percent when compared with the first quarter of 2019. 49
During the pandemic, the Centers for Medicare and Medicaid Services
(CMS) expanded its Medicare reimbursement policy so as to reimburse
providers for telemedicine visits at an equivalent rate to that of in-person
medical visits, thus expanding remote care for elderly citizens. 50 During this
time, telephonic and online remote visits, for multiple demographics, went
from occasional to relatively commonplace for many symptoms and conditions.51 The majority of these visits were those wherein patients were seeking care for non-COVID-19-related conditions.52 Through these remote
visits, patients could receive continuing care for chronic conditions, as well
as evaluation of and treatment for routine minor illnesses. 53 Telemedicine
services also provided crucial resources for physicians in vetting patients
with potential COVID-19 symptoms. 54 Through visits via phone or video,
physicians were able to evaluate patients’ symptoms and, if necessary, send
them for COVID-19 testing at designated locations, thus eliminating the
need for the patient to present in person to the practitioner’s office, potentially exposing others to infection.55
47. Nancy Cleeland, Hospitals Face Staffing Shortages, Reduced Budgets in Coronavirus Pandemic, SHRM (Apr. 7, 2020),
https://www.shrm.org/resourcesandtools/hr-topics/employee-relations/pages/hospitals-facestaffing-shortages-reduced-budgets-in-coronavirus-pandemic.aspx [https://perma.cc/9WNVFTDZ].
48. See generally Lisa M. Koonin et al., Trends in the Use of Telehealth During the
Emergence of the COVID-19 Pandemic, 69 MWWR: U.S. D EP’T HEALTH & H UMAN S ERVS.
1595 (2020),
https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6943a3-H.pdf [https://perma.cc/BY9ZGLTQ].
49. Id.
50. Allison Inserro, CMS Unveils Temporary Change Allowing Wider Use of Telehealth
During
COVID-19
Pandemic,
AJMC
(Mar.
17,
2020),
https://www.ajmc.com/view/cms-unveils-temporary-change-allowing-wider-use-oftelehealth-during-covid19-pandemic [https://perma.cc/4B4Y-7AZ4].
51. See Koonin, supra note 48.
52. Id.
53. See Using Telehealth to Expand Access to Essential Health Services During the
COVID-19 Pandemic, CDC (June 10, 2020),
https://www.cdc.gov/coronavirus/2019-ncov/hcp/telehealth.html
[https://perma.cc/72LVYCZH].
54. Id.
55. Id.
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THE RISE OF DIRECT-TO-CONSUMER ONLINE TELEMEDICINE

While traditional telemedicine services have been in existence for
quite some time, telemedicine’s synthesis with a direct-to-consumer (DTC)
model of marketing and delivery is a newer phenomenon and is experiencing rapid growth in popularity.56 The concept of DTC marketing is geared
towards selling a product, in this case medical care and services, directly to
the ultimate buyer without the use of an intermediary such as a storefront,
or, in this case, the office of a medical professional. 57 The DTC sales model
itself is nothing new. In fact, one of the earliest forms of DTC marketing,
the mail order catalog, is said to date as far back as fifteenth-century Venice.58 Marketing and delivery of medical care in this manner is nothing new,
either. Around the turn of the twentieth century, Americans could place an
order for heroin—used to treat a variety of ailments—through the Sears,
Roebuck catalog and receive, along with their medication, needles and syringes for personal administration.59
Contemporary pharmaceutical companies have long engaged in DTC
marketing practices in the United States, as well.60 Since the late 1990s, the
prevalence of direct-to-consumer advertising (DTCA) by drug companies
has skyrocketed61 primarily due to changes promulgated by the U.S. Food
and Drug Administration (FDA) which relaxed DTCA guidelines.62 DTCA
also increased in prevalence as the baby boomer generation began to age
and as patients became increasingly involved in their own health care deci56. See generally Tanisha Pina, There’s a New Crop of Wellness Brands Bringing
Women’s Health Care into the Digital Space, FASHIONISTA (Nov. 1, 2018),
https://fashionista.com/2018/11/wellness-brands-womens-health-care-digital-medicalservices [https://perma.cc/9C54-N2SJ].
57. Mollie Levy, Comment, Marketing Medicine to Millennials: Preparing Institutions and Regulations for Direct-to-Consumer Healthcare, 55 CAL. W. L. R EV. 521, 523
(2019).
58. See History of Advertising: No 184: A Sears Roebuck Catalogue, CAMPAIGN
(Feb. 14, 2017), https://www.campaignlive.com/article/history-advertising-no-184-searsroebuck-catalogue/1423746 [https://perma.cc/GM52-2WT4].
59. Joe McKendry, Sears Once Sold Heroin, ATLANTIC (Mar. 2019),
https://www.theatlantic.com/magazine/archive/2019/03/sears-roebuck-bayer-heroin/580441/
[https://perma.cc/FG8P-XT8V].
60. Kristina Klara et al., Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines, 33 J. GEN. INTERNAL
MED.
651
(2018),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910340/
[https://perma.cc/6V27-769J]. “Since 1985, the US Food and Drug Administration (FDA)
has allowed direct-to-consumer (DTC) advertising of drugs.” Id.
61. Crystal Adams, Fair Balance and Adequate Provision in Direct-to-Consumer
Prescription Drug Online Banner Advertisements: A Content Analysis, An Entry in the
Journal
of
Medical
Research,
PUBM ED
CENT.
(Feb.
18,
2016),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777882/ [https://perma.cc/EF92-ZEAH].
62. Id.
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sion making.63 Drug manufacturers, who previously aimed their marketing
efforts towards doctors, began focusing such efforts on consumers. 64 Consequently, DTCA has steadily increased in recent years. 65 As of a 2016
study, DTCA spending in the United States reached $6 billion annually, up
from $1.3 billion less than ten years prior.66 Presently, the United States is
the only country in the world, with the exception of New Zealand, that allows DTCA.67 There is no doubt that most, if not all, Americans68 have seen
the cheery, colorful69 ads on television or in magazines, full of happy people who found the right prescription medication to relieve their ailments.70
The ads tell the viewers that they, too, should ask their doctors about these
drugs. 71 These ads seek to market products directly to a targeted patient
population so that these patients, in turn, can arrive at their respective doctors’ offices with a request for a specific prescription medication in mind.72
Given Americans’ abundant access to and usage of the internet,73 there
has never been a better time nor forum for DTC sales, including sales of
63. The Impact of Direct-to-Consumer Advertising, U.S. FOOD & DRUG A DMIN.
(Oct.
23,
2015),
https://www.fda.gov/drugs/information-consumers-and-patientsdrugs/impact-direct-consumer-advertising [https://perma.cc/44EY-6LJ4]; see also Julie
Donohue, A History of Drug Advertising: The Evolving Roles of Consumers and Consumer
Protection,
84
MILLBANK
Q.
659,
682
(2006),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690298/pdf/milq0084-0659.pdf
[https://perma.cc/W35V-5L3N].
64. Donohue, supra note 63, at 659.
65. Lisa M. Schwartz & Steven Woloshin, Medical Marketing in the United States,
1997-2016, 321 J. A M. M ED. ASS’ N 81 (2019),
https://jamanetwork.com/journals/jama/fullarticle/2720029 [https://perma.cc/2MCG-DETE].
66. Id.
67. Zachary Brennan, PhRMA Criticizes FDA’s ‘Unnecessary’ Research on Drug
Advertising
and
Promotion,
REGUL.
FOCUS
(Aug.
16.
2017),
https://www.raps.org/regulatory-focus™/news-articles/2017/8/phrma-criticizes-fda-sunnecessary-research-on-drug-advertising-and-promotion [https://perma.cc/7FJD-2EWP].
68. Donohue, supra note 63, at 659 (“American consumers are bombarded daily
with advertisements for prescription drugs that treat high cholesterol, diabetes, depression,
pain, erectile dysfunction, and a host of other conditions.”).
69. See Klara, supra note 60, at 656 ( “The FDA stated that ads for . . . drugs included distracting scenes and music as well as running text on screen during the risk presentation . . . all of which are discouraged by FDA guidance, as they impair the viewer’s ability
to absorb risk information.”); see also Reenita Das, Are Direct-to-Consumer Ads for Drugs
Doing More Harm Than Good?, FORBES (May 14, 2019, 11:17 AM),
https://www.forbes.com/sites/reenitadas/2019/05/14/direct-to-consumer-drug-ads-are-theydoing-more-harm-than-good/?sh=272d60a54dfc [https://perma.cc/FXR6-ZUUK] ( “The
advertisement released by Bristol-Myers Squibb for Opdivo . . . is full of flashy images of
open skies and vast planes, suggesting an open road to a healthy future.”).
70. See generally Das, supra note 69.
71. Id.
72. Id.
73. See Letter from Pharmaceutical Research and Manufacturers of America
(PhRMA) to FDA (Aug. 11, 2017), https://www.regulations.gov/document?D=FDA-2017-
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medical products and services,74 to thrive.75 Recently, many startups have
realized the lucrative nature of advertising and selling products in a DTC
format on the internet.76 Products offered by these startups run the gamut
from bras77 to razors,78 orthodontic devices79 to eyeglasses, 80 and more.
These companies gear their sales models towards the younger, “digital native” generations which demand an efficient buying experience at an affordable price point.81 As a result, this online DTC sales and delivery model
has become wildly popular among Millennials and Generation Z, generations that exhibit clear preferences for fast and easy online transactions. 82
Therefore, it makes sense that these generations’ preferences for marketing and delivery of general healthcare services would follow suit. 83 Millennials and members of Generation Z are less likely than their predecessors to see a doctor regularly,84 but they also require treatment for basic,
everyday health conditions. While some DTC online platforms scratched
the surface of American healthcare, offering products like invisible braces 85
and contact lenses,86 there was room for ambitious startups to reach into the
underoccupied space of DTC primary care.87 Consequently, health-focused
N-0493-001 [https://perma.cc/8EWT-9VQY] (outlining data regarding increased use of the
internet in recent years among several demographics, particularly as it pertains to consumers’ ability to obtain risk information about pharmaceutical products).
74. Gagne & Helm, supra note 9. “‘As consumers, we’re used to accessing almost
everything else online,’ says Paul Johnson, cofounder and CEO of Lemonaid [an online
DTC telemedicine provider]. ‘Why shouldn’t we access healthcare online if it’s clinically
appropriate and done the right way?’” Id.
75. See generally id.
76. See generally Emily Heyward, How the Smartest DTC Brands Will Evolve, and
What They Can Teach You, INC. (June 2020), https://www.inc.com/magazine/202006/emilyheyward/direct-to-consumer-dtc-digital-native-brand-ecommerce-red-antler.html
[https://perma.cc/AM2H-2D5J].
77. See, e.g., Bras and Underwear for Every Body, THIRDLOVE,
https://www.thirdlove.com [https://perma.cc/XRX4-E3M2].
78. See, e.g., Billie: The New Body Brand, BILLIE, https://mybillie.com
[https://perma.cc/9D89-YZVZ].
79. See, e.g., Clear Aligners, Teeth Straightening and Oral Care,
SMILED IRECTCLUB, https://smiledirectclub.com [https://perma.cc/ZC6Q-VE7K].
80. See, e.g., Glasses and Prescription Eyeglasses, WARBY P ARKER,
https://www.warbyparker.com [https://perma.cc/A36Q-7W5U].
81. See generally Heyward, supra note 76; see also Levy, supra note 57, at 523.
82. See Levy, supra note 57, at 535.
83. See generally Gagne & Helm, supra note 9.
84. Id. “Only 45% of 18-to-29-year-olds even have a primary-care physician, according to a poll from the Kaiser Family Foundation, often due to lack of access or health
insurance.” Id.
85. See, e.g., Clear Aligners, Teeth Straightening and Oral Care, supra note 79.
86. See, e.g., Hubble Contacts, HUBBLE, https://www.hubblecontacts.com/
[https://perma.cc/K8TN-HSTP].
87. Khetpal, supra note 18.
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technology companies88 were founded and thus designed these online DTC
telemedicine platforms in order to connect patients with primary-care
healthcare services.89 These platforms are one of the various mobile health,
or “mHealth,” technologies that have recently made their way to the forefront of modern medicine.90 Services offered by these platforms include,
but are not limited to, migraine prevention and treatment,91 birth control,92
mental healthcare,93 sexual performance,94 and acne treatment,95 as well as a
variety of associated prescriptions.96
These platforms allow patients to access a variety of prescriptions
from the convenience of their preferred electronic devices, providing simple, one-stop shops. 97 The platforms advertise their services and drug offerings on their own webpages; they also run ads on popular social media platforms, like Facebook and Instagram, in an effort to reach target patients. 98
DTC telemedicine platforms differ from typical telemedicine services in
that the patient does not have to first call and schedule an appointment with
a provider as she would with a traditional telemedicine visit.99 Rather, the
patient accesses the website, sees the ad, banner, or link for the medication
that she wants, clicks on the desired product, and is typically100 guided
through a series of questions in order to ascertain the appropriateness of the
medication, including self-reported vitals such as blood pressure and heart
rate.101 The questionnaire is then forwarded to a medical professional—e.g.,
physician, nurse practitioner, or physicians’ assistant—who then evaluates
the patient’s request and reconciles it with the answers in the question88. See, e.g., Thirty Madison: A Human-First Healthcare Company, THIRTY
MADISON, https://thirtymadison.com/ [https://perma.cc/4Q24-7PC8].
89. Khetpal, supra note 18.
90. Gilroy, supra note 27 (“[mHealth] is not only a ‘form of telemedicine using
wireless devices and cell phone technologies’ but also a ‘tool’ through which health care
professionals may practice telehealth and telemedicine.”).
91. See, e.g., Best Medication for Migraine Headaches, supra note 13.
92. See, e.g., Order Birth Control Online with Free, Fast Shipping, NURX,
https://www.nurx.com/ [https://perma.cc/63MG-8HSJ].
93. See, e.g., Hers for Women’s Health, supra note 3.
94. See, e.g., Telehealth for a Healthy, Handsome You, HIMS,
https://www.forhims.com [https://perma.cc/722X-WT7F].
95. See, e.g., Apostrophe: Acne Treatment That Delivers, supra note 14.
96. See JAIN & M EHROTRA, supra note 11. Studies show that users most frequently
access primary-care based DTC telemedicine platforms for prescription treatment of urinary
tract infections, erectile dysfunction, or to access contraception. Id.
97. See Defino, supra note 4.
98. Id.
99. See Gagne & Helm, supra note 9.
100. Id. This depends on the mechanism by which the prescription and consultation
process operates on a site-by-site basis. Id.
101. Id.
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naire.102 In some cases, a virtual visit may be performed via telephone or
video chat.103 Nevertheless, the telemedicine services provided by these
platforms are most frequently provided in an asynchronous, questionnairebased format.104 One physician,105 contracted to provide services for the
men’s health website Hims, reports that he reviews fifteen to twenty patient
files per hour and approves about 70 percent of patient requests. 106 His initial review of a request for a prescription takes about three to five
minutes.107 The review of a request for erectile dysfunction medication consists of verifying the patient’s photo ID, checking the patient’s questionnaire for reports of any underlying health conditions such as heart problems, and providing commentary and insight into the proposed treatment
plan.108 If the request is for something more innocuous, such as medication
for hair loss or acne treatment, the doctor will view photos of the patient
after quickly reviewing the patient’s questionnaire.109
This DTC medicine marketing system effectively works the same way
as a prescription drug television commercial or magazine ad does,110 but
with an efficient twist: it presents patients with medications that may be
suitable for them, but allows the patient to make the initial prescription
choice and have the selection evaluated by a practitioner on the back end. 111
This system eliminates the need to call a physician’s office and wait for an
appointment and it is easy and discreet.112 While these platforms were rap102. Id.
103. Id. (“[This is] similar to what companies such as Dollar Shave Club and Glossier do for razors and cosmetics, except instead of circumventing traditional retailers, the
telemedicine startups skip the brick-and-mortar pharmacy and replace the in-person doctor’s
exam with an online one, sometimes via a video or a phone call, but often merely through an
online questionnaire and brief email correspondence.”).
104. Health Care Law Today Podcast, Episode 4: Direct to Consumer (DTC) Telehealth: Does the Industry Need More Regulation?, FOLEY & LARDNER, transcript (Dec. 11,
2019)
[hereinafter
HCLT
Podcast]
https://1npdf11.onenorth.com/pdfrenderer.svc/v1/abcpdf11/GetRenderedPdfByUrl/DTC%20
Telehealth%20Does%20Industry%20Need%20More%20Regulation.pdf/?url=https%3a%2f%2f
www.foley.com%2fen%2finsights%2fpublications%2f2019%2f12%2fdtc-telehealth-doesindustry-need-more-regulation?format=pdf&attachment=false
[https://perma.cc/JZ9JMJHH].
105. Gagne & Helm, supra note 9.
106. Id.
107. Id.
108. Id.
109. Id.
110. Defino, supra note 4. “[N]ot only [has the U.S.] not outlawed direct-toconsumer ads [like most other countries in the world], but [it has] pretty much invented a
new level of medical marketing [in DTC online medicine].” Id.
111. See generally Gagne & Helm, supra note 9.
112. Id.
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idly gaining popularity prior to the COVID-19 era,113 they proved to be
invaluable resources in the midst of the pandemic.114 As lockdowns and
stay-at-home orders ensued, these platforms provided convenient, ondemand access to patients’ everyday health needs.115 Some even expanded
their offerings to include COVID-19 screenings and assessments.116 These
websites’ newfound popularity, along with their ease of use and accessibility, makes it likely that they will continue to thrive in a post-pandemic environment, as well.117
IV. JUST A PLATFORM
A.

NOT A MEDICAL PROVIDER

While the online DTC telemedicine companies offer telemedicine services and prescription medication to the patients who access their websites,
most DTC telemedicine companies claim that they are not providers of
medical care.118 That is, they claim that when the patients register as users
on the companies’ websites, these patients are not entering into a physicianpatient relationship with the DTC telemedicine company itself, but merely a
“direct customer relationship.”119 The DTC telemedicine company holds
itself out to be a mere intermediary providing a platform for providers,
pharmacies, and patients to connect.120 The patient is, rather, entering into a
physician-patient relationship with certain medical groups with whom the
DTC telemedicine companies partner to provide medical care for registered
users of their websites.121 The companies claim that they do not “control or
interfere with”122 the medical services offered by these independent physicians’ groups and are thus not responsible for things like the “quality and
appropriateness of the care” rendered by these practitioners.123 In fact, certain websites, like Hims and its affiliate Hers, claim that they have not even
113. See generally id.
114. See JAIN & MEHROTRA, supra note 11.
115. Id.
116. Mary Ann Azevedo, Startups Pager, Hims & Hers Boost Telehealth Offerings
to
Address
COVID-19
Pandemic,
CRUNCHBASE
(Apr.
2,
2020),
https://news.crunchbase.com/news/startups-pager-and-hims-hers-boost-telehealth-offeringsto-address-covid-19-pandemic/ [https://perma.cc/AR6Z-LUA3].
117. See generally id.
118. See Gagne & Helm, supra note 9 (explaining how DTC telemedicine companies
seek to “insulate themselves from treatment decisions” by claiming that they are merely
platforms “facilitating interactions between patients and physicians.”).
119. Hims: Terms & Conditions, supra note 25.
120. See Gagne & Helm, supra note 9; see also Defino, supra note 4.
121. Gagne & Helm, supra note 9.
122. See, e.g., Hims: Terms & Conditions, supra note 25.
123. See, e.g., Kick Terms of Use, supra note 25.
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entered into contracts with these groups. 124 These websites claim that they
are merely neutral forums wherein patients can connect with providers,
albeit one wherein the patient enters into a consumer-based relationship
with the website itself.125
Such a setup ostensibly helps the DTC telemedicine companies avoid
allegations of engagement in the corporate practice of medicine, which is
explicitly forbidden in several states.126 The corporate practice of medicine
doctrine, in its broadest form, prohibits corporate entities from employing
physicians to provide medical care to patients. 127 It also prohibits these entities from controlling or interfering with the practice of medicine.128 While
versions of the doctrine vary among the states where it is in effect, its central goals remain the same: to encourage medical practitioners to maintain
professional autonomy and to discourage practitioners from having to divide their loyalties between profit and patient care.129 Theoretically, the
DTC telemedicine companies are not engaging in the corporate practice of
medicine because they partner with “independent” medical practitioners to
provide care to users of the websites. Because these practitioners are
charged with making the ultimate prescribing decision for the patient, the
DTC telemedicine companies can assert that they are not controlling nor
interfering with the physician-patient relationship. Consequently, this setup
helps the DTC telemedicine companies deny liability for the acts of the
providers, a matter which is discussed in further detail in Part V, below.
B.

NOT A PHARMACEUTICAL COMPANY

Just as the DTC telemedicine companies claim that they are not providers of medical care, they also deny that they are pharmaceutical companies.130 This is because the DTC telemedicine companies are not the manufacturers of any of the drugs that they promote or sell.131 Therefore, they are
not subject to the unique regulatory schemes to which pharmaceutical companies are subject.132
Nevertheless, the marketing tactics employed by DTC telemedicine
companies are not dissimilar from those utilized by pharmaceutical companies. The DTC telemedicine companies promote both name-brand and ge124. Hims: Terms & Conditions, supra note 25.
125. See, e.g., id.
126. NAT’L H EALTH LAWS. ASS’N, CORPORATE PRACTICE OF M EDICINE: 50-STATE
SURVEY (1996).
127. Amer, supra note 35, at 498.
128. Id. at 499.
129. Id. at 499-500.
130. See Defino, supra note 4.
131. See, e.g., Hims: Terms & Conditions, supra note 25.
132. Defino, supra note 4. See also HCLT Podcast, supra note 104.
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neric versions of prescription drugs on their own websites, as well as
through other channels, including social media. For example, on the websites Hims and Hers, users can click on headings including, but not limited
to, “Primary Care,” “Sex,” “Skin,” and “Mental Health.”133 Under those
headings, users will find lists of prescription medications used to treat several conditions coupled with witty phrasing and playful photos. 134 Included
with this promotional material are descriptions of the medication’s use,
limited safety information, a link to access additional safety information, a
notice to users regarding a physician consultation, and a button to begin the
consultation.135 This promotional process is an efficient, streamlined form
of DTCA, similar to that which Americans are accustomed to seeing on
television or in magazines. The DTC telemedicine companies also advertise
on social media platforms136 including Instagram and Facebook.137
DTCA by pharmaceutical companies is primarily regulated by the
FDA.138 The FDA has authority to oversee promotion of prescription drugs
under the Food, Drug, and Cosmetic Act (FDCA).139 Over the years, the
FDA’s efforts have largely focused on ensuring that pharmaceutical companies, in advertising their products directly to patients, create a “fair balance”140 between benefit and risk information as it pertains to drugs advertised, particularly in broadcast advertisements. 141 This is so patients are not
misled into thinking that an advertised medication has overwhelming benefits with few risks and can thus make more informed healthcare decisions.142
Over approximately the last four decades, American patients have become increasingly involved in their healthcare decision making as a result
of various factors, including but not limited to the patients’ rights movement of the 1970s143 and the aging of the baby boomer generation.144 Thus,
133. Telehealth for a Healthy, Handsome You, supra note 94.
134. See, e.g., Stendra (avanafil) Tablets, HIMS, https://www.forhims.com/erectiledysfunction/stendra [https://perma.cc/BJ45-UARB] (welcoming users to the landing page
for Stendra, an erectile dysfunction medication, with a tagline reading “fast and furious”
followed by photos of eggplants of various sizes as well as a suggestive cactus).
135. Id.
136. See Defino, supra note 4; Gagne & Helm, supra note 9.
137. See, e.g., Apostrophe, 6 Reasons to Ditch the Dermatologist’s Office and Use
Apostrophe,
FACEBOOK
(Jan.
7,
2021,
1:11
PM),
www.facebook.com
[https://perma.cc/D7KL-6QPF] (a Facebook ad promoting the use of antibiotics for acne
treatment).
138. See 21 U.S.C. §§ 351-360.
139. Id.
140. Adams, supra note 61; 21 C.F.R. § 202.1(e)(5)(ii) (2021).
141. U.S. FOOD & DRUG A DMIN., supra note 63.
142. Id.
143. Donohue, supra note 63, at 662.
144. U.S. FOOD & DRUG A DMIN., supra note 63.
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DTCA provided another avenue for patients to be active participants in
their medical care.145 Nevertheless, influential entities including the American Medical Association (AMA) have long cautioned146 the use of DTCA
due to the ads’ potentially negative effects on a populace comprised primarily of non-physicians.147 Even pharmaceutical companies themselves were
once hesitant to endorse DTCA of their products, arguing that “DTCA
would hurt the doctor-patient relationship, confuse an unsophisticated public, and lead to higher drug costs.” 148
Consequently the FDA concluded that, if DTCA would be permitted,
patients should be equipped with information so that they could make informed decisions about the products advertised.149 The FDA’s “fair balance” requirement came as part of its 1999 final guidance150 to the pharmaceutical industry regarding advertising prescription drugs in broadcast media, including television and radio.151 DTC pharmaceutical advertisements
often contain an abundance of attractive imagery and happy patients alongside statements which proclaim a medication’s abundant benefits. 152 This
positive imagery makes it so that a patient’s attention could easily be drawn
away from any risks or dangers of an advertised medication.153 Therefore,
the FDA promulgated guidelines stating that pharmaceutical companies
engaging in broadcast DTCA should provide, within those broadcast advertisements, a “major statement”154 regarding the medication’s side effects
and contraindications.155 This statement must be spoken aloud and clearly
articulate the drug’s most important risks. 156 Additionally, “adequate provision”157 must be made so as to disseminate all other relevant information
145. Donohue, supra note 63, at 662.
146. Id. at 665. As early as the early 1900s, the AMA cautioned physicians against
prescribing “drugs that were ‘advertised directly to the laity.’” Id.
147. See, e.g., Press Release, Am. Med. Ass’n, AMA Calls for Ban on DTC Ads of
Prescription Drugs and Medical Devices (Nov. 17. 2015), https://www.ama-assn.org/presscenter/press-releases/ama-calls-ban-dtc-ads-prescription-drugs-and-medical-devices
[https://perma.cc/4WJY-XULH].
148. Donohue, supra note 63, at 678.
149. Id. at 662.
150. U.S. FOOD & DRUG A DMIN., G UIDANCE FOR INDUSTRY: CONSUMER -DIRECTED
BROADCAST
ADVERTISEMENTS
(1999),
https://www.fda.gov/media/75406/download
[https://perma.cc/E3VP-DH2G].
151. Adams, supra note 61.
152. Klara, supra note 60, at 656.
153. Id.
154. 21 U.S.C. § 352(n); Drug Advertising: A Glossary of Terms, U.S. FOOD & DRUG
ADMIN. (Jan. 19, 2020) [hereinafter FDA Glossary], https://www.fda.gov/drugs/prescriptiondrug-advertising/drug-advertising-glossary-terms#M [https://perma.cc/G24K-SK92].
155. Adams, supra note 61; 21 U.S.C. § 352(n)
156. Adams, supra note 61.
157. 21 C.F.R. § 202.1(e)1 (2021).
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about the medication—namely that which is included on the drug’s FDAapproved labeling.158 This must appear in the ad itself, or alternatively, a
“brief summary” of all risks and side effects must be provided.159 “Brief
summaries” are still required in printed pharmaceutical ads and would realistically take several minutes to recite in a broadcast ad.160 Thus, pharmaceutical ads in broadcast form typically make “adequate provision” through
providing an alternate means of accessing full information about the drug,
such as a 1-800 number, a website, a statement advising patients to ask their
doctors about the medication, and/or a citation to an alternative print resource where the information is written,161 e.g., “[s]ee our ad in Family Circle.”162 Printed advertisements163 also must include the statement, “You are
encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch,164 or call 1-800-FDA-1088.”165
FDA regulation of pharmaceutical promotion on the internet, however,
is not quite as clear and has not kept up with rapid advancements in technology and prolific internet usage.166 The FDA has commented that the
internet is not analogous to either print or broadcast methods of advertising.167 While the FDA previously planned on developing internet-specific
guidelines, it suspended the project, citing an inability to keep up with rapid
technological developments.168 Currently, the FDA looks at internet pharmaceutical promotion more or less on a case-by-case basis, determining
whether individual promotions constitute “labeling, advertising, or neither”
and evaluating them accordingly.169 It has also issued guidelines which per158. Id.
159. Id.
160. Adams, supra note 61.
161. Id.
162. See, e.g., TOP Branding, Otezla TV Commercial: ‘Little Things Can Be a Big
Deal’, YOUTUBE (May 15, 2020), https://www.youtube.com/watch?v=Z7HiEPLynkE
[https://perma.cc/C53P-H8JR]
(demonstrating an example of “adequate provision” in Otezla commercial).
163. Product Claim Ad (Correct), U.S. FOOD & DRUG A DMIN. (Dec. 23, 2015),
https://www.fda.gov/drugs/prescription-drug-advertising/product-claim-ad-correct
[https://perma.cc/PP86-2L8Z] (demonstrating an example of a correct product claim ad).
164. MedWatch: The FDA Safety Information and Adverse Event Reporting Program, U.S. FOOD & DRUG A DMIN. (Feb. 19, 2021), https://www.fda.gov/safety/medwatchfda-safety-information-and-adverse-event-reporting-program
[https://perma.cc/TT2VVY2V].
165. 21 U.S.C. § 352.
166. J.W. SCHOMISCH, FDA A DVERTISING AND PROMOTION M ANUAL ¶ 428 (2018),
Westlaw 7893161.
167. Consumer-Directed Promotion; Public Meeting, 68 Fed. Reg. 47920, 47922
(Aug. 12, 2003).
168. SCHOMISCH, supra note 166.
169. Id.
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tain to the use of social media for drug promotion,170 particularly those for
advertising on social media platforms with space limitations, like Twitter. 171
These guidelines focus on ensuring that the ads convey truthful and accurate information to viewers, as well as ensuring that risk and benefit information are presented in “fair balance” with each other so as not to mislead
the consumer.172
The Office of Prescription Drug Promotion (OPDP),173 a division of
the FDA, has performed studies on topics including online DTC drug promotion,174 which included a study of placement of risk information on DTC
prescription drug websites.175 OPDP researchers also conducted a study on
DTC drug promotion via the internet and mobile devices. 176 Ultimately,
when evaluating DTC prescription drug promotion in absence of more specifically internet-tailored regulation, both the FDA and the OPDP focus
their efforts on ensuring that there is a fair balance between risks and benefits articulated on internet ads.177 The OPDP also fields complaints from
healthcare providers who identify and report false or misleading drug advertisements through its “Bad Ad Program.”178
This elaborate framework is in place in order to regulate DTCA by
pharmaceutical companies. Decades of care and deliberation has gone into
promulgating rules to ensure that risks and benefits are adequately con170. For Industry: Using Social Media, U.S. FOOD & DRUG ADMIN. (Sept. 4, 2020),
https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/industry-usingsocial-media [https://perma.cc/YS4K-W79L].
171. U.S. FOOD & DRUG A DMIN., G UIDANCE FOR INDUSTRY: INTERNET/SOCIAL MEDIA
PLATFORMS WITH CHARACTER SPACE LIMITATIONS— PRESENTING RISK AND BENEFIT
INFORMATION FOR PRESCRIPTION DRUGS AND M EDICAL D EVICES (2014),
https://www.fda.gov/media/88551/download [https://perma.cc/2JGY-WNRG].
172. Id.
173. The Office of Prescription Drug Promotion (OPDP), U.S. FOOD & DRUG
ADMIN. (Jan. 27, 2021), https://www.fda.gov/about-fda/center-drug-evaluation-and-researchcder/office-prescription-drug-promotion-opdp [https://perma.cc/Z3EL-3R35].
174. The Office of Prescription Drug Promotion (OPDP) Research: Examination of
Online DTC Drug Promotion (Completed in 2016), U.S. FOOD & DRUG A DMIN. (May 7,
2020),
https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/officeprescription-drug-promotion-opdp-research#examination [https://perma.cc/V9UX-PRNR].
175. Helen W. Sullivan, Abstract: Placement and Format of Risk Information on
Direct-to-Consumer Prescription Drug Websites, TAYLOR & FRANCIS (Jan. 27, 2017),
https://www.tandfonline.com/doi/full/10.1080/10810730.2016.1258745
[https://perma.cc/7NHD-37VB].
176. Kathryn Aikin et al., Direct-to-Consumer Promotion of Prescription Drugs on
Mobile
Devices:
Content
Analysis,
J. MED. INTERNET
RSCH.
(2017),
https://www.jmir.org/2017/7/e225/ [https://perma.cc/FLS7-F5RJ].
177. See id., see also Adams, supra note 61.
178. The Bad Ad Program, U.S. FOOD & DRUG A DMIN. (Jan. 5, 2021),
https://www.fda.gov/drugs/office-prescription-drug-promotion/bad-ad-program
[https://perma.cc/K32G-739P].
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veyed to consumers. 179 However, although DTC telemedicine companies
engage in DTCA both on their individual websites and on social media, this
regulatory framework does not directly apply to them because they are not
pharmaceutical companies.180 Rather, the DTC telemedicine companies
“comply with content requirements for media platforms [that they] utilize.”181 Furthermore, there is nothing specifically prohibiting the DTC telemedicine companies from promoting medication for off-label, non-FDA
approved uses on both their websites and social media.182
C.

NOT AN ONLINE PHARMACY

The DTC telemedicine companies claim that they are not online pharmacies, either. This is because they partner with separate online pharmacies
to fulfill orders for medications prescribed by the independent providers. 183
Nevertheless, DTC telemedicine companies share some common characteristics with online pharmacies, and thus regulatory schemes related to online
pharmacies should be examined in turn.
Historically, agencies and legislators have struggled with how to regulate online pharmacies because of the pharmacies’ diverse characteristics. 184
While some operate much like brick-and-mortar pharmacies185—the patient
visits a doctor, the doctor prescribes a medication, and the online pharmacy
fills the prescription order accordingly186—others operate in a similar manner to DTC telemedicine companies. In those cases, a patient may go to an
online pharmacy’s website, complete a questionnaire, and be remotely prescribed a medication by a physician.187 The prescription is then fulfilled by
the pharmacy.188 Furthermore, there are online pharmacies known as
“rogue” pharmacies which dispense medications without valid prescriptions, as well as foreign online pharmacies from which patients can order
medications originating from locations outside of the United States. 189
While regulation of foreign online pharmacies has proven difficult,190 do179. See Donohue, supra note 63, at 665-85.
180. Gagne & Helm, supra note 9.
181. Defino, supra note 4.
182. Id.
183. See, e.g., Hims: Terms & Conditions, supra note 25.
184. See generally Bob Schultz, Online Pharmacy Regulation: How the Ryan Haight
Online Pharmacy Consumer Protection Act Can Help Solve an International Problem, 16
SAN DIEGO INT’L L.J. 381, 381-85 (2015).
185. Id. at 385.
186. Id.
187. Id. at 386.
188. Id.
189. Schultz, supra note 184, at 385-86.
190. Id.
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mestic online pharmacies are primarily regulated by the FDA under the
FDCA191 and the Drug Enforcement Administration (DEA) under the Controlled Substances Act of 1974 (CSA).192 Additionally, the Federal Trade
Commission (FTC) may take action against online pharmacies whose websites make false or misleading statements, or those who misrepresent the
safety or efficacy of a medication.193
Congress has legislated in this area as recently as 2008, with patient
safety serving as the driving force behind the legislation.194 The Ryan
Haight Online Pharmacy Consumer Protection Act of 2008 (hereinafter the
“Ryan Haight Act” or the “Act”) 195 amended the CSA and was enacted in
response to the tragic death of a teenager who procured prescription drugs
from an online pharmacy.196 Haight was able to purchase prescription painkillers online with a prescription remotely provided by a physician whom
he had never met.197 He subsequently overdosed.198 The Ryan Haight Act
imposed new restrictions upon online pharmacies, targeting “rogue” pharmacies and those that engage in remote prescribing.199 Its primary aim was
to restrict access to dangerous controlled substances,200 including prescription painkillers, which were being generously prescribed and distributed by
means of the internet. Most notably, the Ryan Haight Act mandates, with
limited exceptions, that no controlled substance may be dispensed over the
internet without a valid prescription from a practitioner who has conducted
at least one in-person medical evaluation of the patient.201 The Act also
mandates that online pharmacies obtain a separate DEA registration allowing them to operate as internet-based pharmacies dispensing controlled substances.202 Furthermore, online pharmacies must report the quantity of controlled substances dispensed on a monthly basis unless the amounts dispensed fall below certain designated thresholds.203 Additionally, each
191. 21 U.S.C. § 331.
192. 21 U.S.C. §§ 801-904.
193. Kerry Toth Rost, Policing the “Wild West” World of Internet Pharmacies, 76
CHI. K ENT L. REV. 1333, 1348 (2000).
194. Jeff Karberg, Progress in the Challenge to Regulate Online Pharmacies, 23 J.L.
& HEALTH 113, 114 (2010).
195. Ryan Haight Online Pharmacy Consumer Protection Act of 2008, Pub. L. No.
110–425, 122 Stat. 4820.
196. Karberg, supra note 194, at 114.
197. Id.
198. Id.
199. Id. at 116-18.
200. A controlled substance is a drug or substance that is listed in Schedules I
through V of the CSA. 21 U.S.C. § 802.
201. 21 U.S.C. § 829(e).
202. 21 U.S.C. § 823(f).
203. Id.
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pharmacy must prominently display on its website a statement of compliance with the Act204 as well as certain information and disclosures. 205
A notable, yet narrow exception to the in-person evaluation requirement exists for “practitioner[s] engaged in the practice of telemedicine.” 206
The Act defines “practice of telemedicine” as “the practice of medicine . . .
by a practitioner (other than a pharmacist) who is at a location remote from
the patient and is communicating with the patient, or health care professional who is treating the patient, using a telecommunications system . . .
.”207 The definition then goes on to enumerate seven specific circumstances
wherein a provider has sufficient medical information in order to prescribe
a controlled substance to a patient remotely, without conducting an inperson evaluation.208 These circumstances include those where: (1) the patient is being treated, and is physically located, in a hospital by a separate,
licensed practitioner within that facility; (2) the patient is being treated by,
and in the presence of, another practitioner in the “usual course of professional practice;” (3) the patient is prescribed controlled substances via telemedicine by a practitioner “who is an employee or contractor of the Indian
Health Service, or is working for an Indian tribe or tribal organization under

Id.

204.
205.

21 U.S.C. § 831(a).
21 U.S.C. § 831(c). Information and disclosures include:
(1) The name and address of the pharmacy as it appears on the
pharmacy’s Drug Enforcement Administration certificate of
registration. (2) The pharmacy’s telephone number and email
address. (3) The name, professional degree, and States of licensure of the pharmacist-in-charge, and a telephone number
at which the pharmacist-in-charge can be contacted. (4) A list
of the States in which the pharmacy is licensed to dispense
controlled substances. (5) A certification that the pharmacy is
registered under this part to deliver, distribute, or dispense by
means of the Internet controlled substances. (6) The name, address, telephone number, professional degree, and States of licensure of any practitioner who has a contractual relationship
to provide medical evaluations or issue prescriptions for controlled substances, through referrals from the website or at the
request of the owner or operator of the website, or any employee or agent thereof. (7) The following statement, unless
revised by the Attorney General by regulation: “This online
pharmacy will only dispense a controlled substance to a person
who has a valid prescription issued for a legitimate medical
purpose based upon a medical relationship with a prescribing
practitioner. This includes at least one prior in-person medical
evaluation or medical evaluation via telemedicine in accordance with applicable requirements of section 309.”

206.
207.
208.

21 U.S.C. § 829(e)(3)(A).
21 U.S.C. § 802(54).
21 U.S.C. § 802(54)(A)-(G).
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its contract or compact with the Indian Health Service under the Indian
Self-Determination and Education Assistance Act;” (4) there is a public
health emergency; (5) a practitioner has obtained “special registration” status; (6) there is a medical emergency that prevents a patient from being
physically present at a Department of Veterans Affairs medical facility; and
(7) there exist other circumstances determined by subsequent regulations.209
As evidenced by these narrow exceptions, the Ryan Haight Act recognizes telemedicine’s value in remote prescribing while taking care to not
overextend the reach of this mode of healthcare delivery, at least in the
realm of controlled substances. Furthermore, the Act expressly prohibits
online pharmacies from “offering to fill a prescription for a controlled substance based solely on a consumer’s completion of an online medical questionnaire.”210 Nevertheless, the Act does not impose any significant limitations on the remote prescribing of drugs that are non-controlled substances,
that is, drugs that fall outside of Schedules I through V of the CSA.211 Such
drugs include, but are not limited to, “lifestyle drugs” such as those for
weight loss and erectile dysfunction.212 Online prescribing is attractive to
those who wish to be discreet in their procurement of medications for conditions of this nature but, some drugs, like those prescribed for erectile dysfunction, can have potentially serious side effects.213 Thus, critics have noted that while the Ryan Haight Act was a meaningful step towards regulation of online pharmacies, it fell short in controlling predatory prescribing
of “non-controlled” substances.214
While DTC telemedicine companies are not online pharmacies, it is
helpful to examine online pharmacy regulation in light of the proliferation
of DTC telemedicine. The concerns that exist regarding remote, questionnaire-driven prescribing in an online pharmacy context also exist in the
DTC telemedicine context, albeit not in the realm of controlled substances.
However, critics’ concerns regarding the ease of online prescribing of “lifestyle drugs” carry over to DTC telemedicine. DTC telemedicine companies
often cater to individuals who seek some level of anonymity or discretion
for conditions regarding sexual performance or mental health.215 Thus, concerns arise when physicians remotely prescribe lifestyle drugs, some of
which are prescribed for off-label, non-FDA approved uses, through DTC
telemedicine websites in an asynchronous, questionnaire-driven format.
209.
210.
211.
212.
213.
214.
215.

Id.
21 U.S.C. § 841(h).
See generally Karberg, supra note 194, at 137-39.
Id. at 137-38.
Id. at 138.
Schultz, supra note 184, at 404-05.
Brown & De Vynck, supra note 6.
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V. OVERVIEW OF OFF-LABEL DRUG MARKETING AND PRESCRIBING
A. DEFINITION OF OFF-LABEL PRESCRIPTIONS AND REGULATORY OVERVIEW

Pursuant to its authority under the FDCA, the FDA conducts extensive
testing of prescription medications in an effort to ensure that these medications are safe and effective for the conditions that they are intended to
treat.216 However, a certain medication may treat multiple symptoms or
conditions, including conditions for which a drug has not been approved by
the FDA. Off-label prescriptions are those which are prescribed for uses
other than the uses that have been approved by the FDA.217 These are also
sometimes called “non-approved” uses. 218 For example, the beta-blockers
atenolol and propranolol, medications which are FDA-approved for treatment of certain cardiac issues, are sometimes prescribed off-label to treat
symptoms of anxiety.219
Generally, after the FDA approves a drug for use, physicians have
broad discretion to prescribe it for this intended (approved) use as well as to
treat other conditions, even if the drug has not been FDA approved for
those conditions.220 These physician prescribing practices do not violate
federal law or circumvent FDA regulations because the FDA does not regulate the practice of medicine,221 only the marketing and distribution of
drugs. 222 Off-label prescribing has been proven to be critical in some therapeutic areas, like oncology,223 where the FDA approval process may lag
behind research findings.224 Moreover, off-label prescribing may ultimately
lead to FDA approval of additional uses for a medication.225 For example,
Topiramate, also known as Topamax, a drug that was initially FDAapproved solely as an anticonvulsant (an anti-seizure medication) was frequently prescribed off-label for prevention of migraine headaches in those
216. Monique C.M. Leahy, Off-Label Use of Prescription Medications, 124 A M. J UR.
TRIALS 487, § 2 (2012); see also 21 U.S.C. § 355.
217. Leahy, supra note 216, at § 1.
218. Id.
219. Zawn
Villines,
Beta-Blockers
for
Anxiety:
What
to
Know,
MEDICALNEWS TODAY (Sept. 19, 2019), https://www.medicalnewstoday.com/articles/326397
[https://perma.cc/EYV4-4RAS].
220. Leahy, supra note 216, at § 1.
221. Nathan Cortez, The Statutory Case Against Off-Label Promotion, 83 U. CHI. L.
REV. 124 (2016); see also 21 U.S.C. § 396.
222. Leahy, supra note 216, at § 1.
223. Cortez, supra note 221, at 124-25.
224. Id. at 133-34.
225. See Richard Wenzel, Ask the Pharmacist: Off-Label Prescribing—Why Drugs
Ranging from Antidepressants to Anti-Seizure Medications Are Used for Headache Management, NAT’L HEADACHE FOUND., https://headaches.org/2007/11/01/ask-the-pharmacistarchive-mayjune-2007/ [https://perma.cc/5WZD-QRA2].
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who suffered from chronic migraine.226 In 2004, the FDA approved Topiramate as a migraine preventative.227
While doctors can and do generally prescribe off-label medications for
unapproved uses when they deem such uses medically appropriate, 228
pharmaceutical companies are subject to more scrutinous regulation when it
comes to promotion of medication for off-label uses. 229 While a 2012 federal court decision held that the FDCA “do[es] not expressly prohibit the
‘promotion’ or ‘marketing’ of drugs for off-label use,”230 the FDA maintains a functional ban on off-label promotion by prohibiting pharmaceutical
advertisements for uses that have not been FDA-approved.231 Such DTC
advertisements could be deemed “false, lacking in fair balance, or otherwise
misleading”232 and, consequently, could subject the pharmaceutical manufacturer to significant penalties.233 A drug could be deemed mislabeled or
misbranded if the “written, printed, or graphic matter . . . accompanying
[the drug]”234 is false or misleading.235 The Supreme Court has interpreted
the language “accompanying [the drug]” to include materials that may explain or supplement the drug; a textual relationship is implied and no physical attachment between the drug and the ancillary materials is necessary. 236
Therefore, while recent federal court decisions have allowed off-label
promotions to be directed towards physicians on the basis of First Amendment protections,237 pharmaceutical companies must continue to proceed
with caution when marketing off-label uses directly to patients through
DTCA so that their advertisements are not deemed false or misleading and
so that their drugs are not deemed mislabeled or misbranded.238
226. Id.
227. Jennifer Warner, FDA Approves Topamax for Preventing Migraines, WEBMD
(Aug. 12, 2004), https://www.webmd.com/migraines-headaches/news/20040812/fdaapproves-topamax-preventing-migraines [https://perma.cc/T82X-JQ2K].
228. Cortez, supra note 221, at 124.
229. See generally id. at 125-26.
230. United States v. Caronia, 703 F.3d 149, 154 (2d Cir. 2012).
231. 21 C.F.R. § 202.1(e)(6)(i) (2021).
232. Id.
233. 21 U.S.C. § 333(g).
[A]ny such person [individual, partnership, corporation, or association]
who disseminates or causes another party to disseminate a direct-toconsumer advertisement that is false or misleading shall be liable to the
United States for a civil penalty in an amount not to exceed $250,000 for
the first such violation in any 3-year period, and not to exceed $500,000
for each subsequent violation in any 3-year period.
Id.
234. 21 U.S.C. § 321(m); see also 21 C.F.R. § 1.3(a) (2021).
235. 21 U.S.C. § 352.
236. Kordel v. United States, 335 U.S. 345, 350 (1948).
237. See, e.g., United States v. Caronia, 703 F.3d 149, 152 (2d Cir. 2012).
238. See generally Cortez, supra note 221, at 124-28.
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PROBLEMS WITH OFF-LABEL PRESCRIBING AND PROMOTION

While there are plentiful benefits239 to off-label drug prescribing, promotion, and usage, there are dangers as well.240 A 2012 study found that 79
percent of off-label uses as prescribed by primary care physicians “lacked
strong scientific evidence” of efficacy as it pertains to a particular treatment.241 A subsequent study found that off-label use of medications which
lacked strong scientific evidence of efficacy for a particular treatment were
associated with a 44 percent greater likelihood of adverse events when
compared to approved uses.242 Types of medications most frequently prescribed off-label include anticonvulsants, antipsychotics, and antidepressants, 243 all of which can lend themselves to dangerous side effects244 if not
prescribed properly and managed carefully in conjunction with a patient’s
other medications.245
Additionally, there is a societal and governmental concern that offlabel use may expose patients, who are increasingly involved in their
healthcare decision making,246 to considerable harm if marketing thereof is
not carefully monitored.247 Studies have shown that DTC broadcast advertisements regularly promote off-label use through the language and
graphics used in commercials,248 and “few ads [are] fully compliant with
FDA guidelines for DTC advertising.”249 Consumer groups have voiced
their concerns to the FDA over misleading statements in DTC broadcast ads
239. See id. at 124-25.
240. Id. at 125.
241. Tewodros Eguale et al., Drug, Patient, and Physician Characteristics Associated with Off-Label Prescribing in Primary Care, 172 ARCHIVES INTERNAL M ED. 781, 783
(2012),
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1149634?appid=scweb&
alert=article [https://perma.cc/Q278-7B8C].
242. Cortez, supra note 221, at 125; see generally Tewodros Eguale et al., Association of Off-label Drug Use and Adverse Drug Events in an Adult Population, 176 JAMA
INTERNAL M ED. 55 (2016),
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2467782
[https://perma.cc/G4FR-Z5JC].
243. Eguale, supra note 241, at 781, 783.
244. See, e.g., James M. Ferguson, SSRI Antidepressant Medications: Adverse Effects
and
Tolerability,
3
J.
CLINICAL
PSYCHIATRY
22
(2001),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC181155/
[https://perma.cc/L3RP-42WU];
Jim Thigpen et al., Behavioral Side Effects of Antiepileptic Drugs, U.S. P HARMACIST (Nov.
15, 2013), https://www.uspharmacist.com/article/behavioral-side-effects-of-antiepilepticdrugs [https://perma.cc/DF6Z-MM7R].
245. See Eguale, supra note 242, at 59.
246. See supra text accompanying notes 143-45.
247. Cortez, supra note 221, at 125.
248. See Klara, supra note 60, at 656.
249. Id. at 657.
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which imply off-label uses for purposes such as weight loss. 250 Furthermore, it has been suggested that prohibitions on off-label promotion via
DTCA have not been fully enforced by the FDA.251
Nevertheless, over the last few decades, pharmaceutical companies
have paid tens of billions of dollars to settle actions that alleged illegal offlabel marketing of prescription medications, including those marketed directly to physicians.252 Many of these actions253 have been brought under
the False Claims Act (FCA).254 The FCA is a broad remedial statute intended to protect the U.S. federal government from fraud.255 It imposes civil
liability on those who cause the government to make payments that should
not otherwise be made.256 In the present context, it has been used to impose
substantial penalties upon pharmaceutical manufacturers that “knowingly
‘caused or induced’”257 physicians to prescribe medications for off-label,
non-FDA approved uses, thus causing false or fraudulent claims to be submitted to and, consequently, payments made by Medicaid and Medicare. 258
While the FDCA does not provide a private right of action against pharmaceutical manufacturers who engage in prohibited off-label marketing,259 the
FCA allows “qui tam,”260 or whistleblower, actions to be brought by individuals who allege violations.261 Additionally, FCA violations carry penalties between $5,000 and $10,000 per false or fraudulent claim submitted, as
250. See, e.g., Letter from Public Citizen to Thomas Abrams, MD, Director, Office
of
Prescription
Drug
Promotion
(Mar.
31,
2015),
http://www.citizen.org/documents/2250.pdf [https://perma.cc/7H5K-E3QX].
251. See Klara, supra note 60, at 657.
252. Cortez, supra note 221, at 125; see generally S AMMY A LMASHAT ET AL.,
TWENTY-FIVE YEARS OF P HARMACEUTICAL INDUSTRY CRIMINAL AND CIVIL P ENALTIES : 1991
THROUGH
2015
(2016),
https://www.citizen.org/wp-content/uploads/2311_0.pdf
[https://perma.cc/7EK3-TJFU].
253. ALMASHAT, supra note 252, at 10.
254. 31 U.S.C. §§ 3729-3733.
255. Stephanie Greene, False Claims Act Liability for Off-Label Promotion of Pharmaceutical Products, 110 P ENN ST. L. REV. 41, 54-55 (2005).
256. Id.
257. Katherine A. Blair, Comment, In Search of the Right Rx: Use of the Federal
False Claims Act in Off-Label Drug Promotion Litigation, 23 H EALTH LAW . 44, 47 (2011).
258. Id.
259. Rather, the FDA may seize the illegally promoted drugs, issue an injunction
against further promotion of the off-label uses, or institute criminal proceedings against the
manufacturer. 21 U.S.C. §§ 332-334.
260. U.S. D EP’T OF JUST., F ALSE C LAIMS ACT : A PRIMER (2011),
https://www.justice.gov/sites/default/files/civil/legacy/2011/04/22/CFRAUDS_FCA_Primer.pdf. [https://perma.cc/SC7K-NAD5]. “The FCA allows private
persons to file suit for violations of the FCA on behalf of the government. A suit filed by an
individual on behalf of the government is known as a ‘qui tam’ action, and the person bringing the action is referred to as a ‘relator.’” Id.
261. ALMASHAT, supra note 252, at 10.
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well as a provision for imposition of treble damages. 262 Thus, the FCA
serves as a powerful tool against off-label promotion.
VI. CONCERNS WITH OFF-LABEL PROMOTION AND PRESCRIBING IN AN
ONLINE DIRECT-TO-CONSUMER FORMAT
A.

LIKE TRADITIONAL DTCA, BUT NOT REGULATED THAT WAY

The promulgation of rules for promotion of pharmaceuticals in the
United States predated the advent of online direct-to-consumer
healthcare.263 While there is a robust regulatory framework in place to regulate pharmaceutical companies and how they market their products for offlabel uses, there is no specific, substantive regulation in place for DTC
online telemedicine websites.264 Furthermore, since most modern online
DTC telemedicine companies do not accept insurance, 265 including Medicare or Medicaid, enforcement of illegal off-label promotion under the FCA
is also unlikely. Therefore, promotion of prescription medication for offlabel uses goes largely unchecked on DTC telemedicine websites, thus
lending itself to some inherent dangers. 266
For example, Hims markets and sells Sertraline, an antidepressant in
the Selective Serotonin Reuptake Inhibitor (SSRI) class—also known by its
brand name, Zoloft—for off-label use, specifically for treatment of premature ejaculation.267 As noted in Part III above,268 sites like Hims target patients from younger generations, specifically Millennials and members of
Generation Z. Millennials are typically defined as those individuals born
between 1981 and 1996 and Generation Z is defined as those born between
1997 and 2012.269 Of notable concern is the fact that Sertraline, like several

262. 31 U.S.C. § 3729.
263. See generally Brown & De Vynck, supra note 6.
264. See Gagne & Helm, supra note 9.
265. See, e.g., Will Insurance Cover Prescriptions for Hims and Hers?, HIMS (Oct.
19, 2017),
https://support.forhims.com/hc/en-us/articles/115002248351-will-insurance-coverprescriptions-for-hims-hers- [https://perma.cc/EQS7-D8EJ]; FAQ: Does Kick Accept Insurance?, KICK, https://www.gokick.com/faq/ [https://perma.cc/AVY6-TF2M].
266. See Brown & De Vynck, supra note 6.
267. Sertraline for Premature Ejaculation, supra note 15; see also Sertraline,
DRUGS.COM
(Aug.
13,
2020),
https://www.drugs.com/ppa/sertraline.html [https://perma.cc/T3NW-YR9M].
268. See supra text accompanying notes 82-89.
269. Michal Dimock, Defining Generations: Where Millennials End and Generation
Z Begins, PEW RSCH. CTR. (Jan. 17, 2019), https://www.pewresearch.org/facttank/2019/01/17/where-millennials-end-and-generation-z-begins/ [https://perma.cc/LDT6DSYY].
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antidepressants,270 carries a black box warning,271 also known as boxed
warning, 272 notifying patients of potentially serious side effects in individuals up to twenty-four years of age.273 This warning specifically addresses an
increased risk of suicidal ideation or actions among individuals in this age
range.274 As noted above,275 the FDA has not specifically regulated internet
promotion and advertisement of prescription medication. However, it is
worth noting that, on Zoloft’s website, the black box warning appears immediately upon entry to the site.276 It is front and center, nearly impossible
for the viewer to miss, and immediately juxtaposed with some attractive
features of the medication. This is likely to comply with the FDA requirements of “fair balance,” so that the viewer of the website does not overlook
this medication’s most dangerous side effect while reviewing the medication’s benefits.
However, on the Hims website, the format is much different.277 After
clicking on “Sertraline for Premature EjaculationRX”278 under the heading of
270. See Dien Ho, Antidepressants and the FDA’s Black-Box Warning: Determining
a Rational Public Policy in the Absence of Sufficient Evidence, 14 VIRTUAL MENTOR 483,
484 (2012), https://journalofethics.ama-assn.org/article/antidepressants-and-fdas-black-boxwarning-determining-rational-public-policy-absence-sufficient/2012-06
[https://perma.cc/GEE3-97QN].
271. FDA Glossary, supra note 154 (“Drugs that have special problems, particularly
ones that may lead to death or serious injury, may have this [type of] warning information
displayed within a box in the prescribing information.”).
272. Id.
273. Important Safety Information and Indications, Zoloft.com Black Box Warning,
ZOLOFT,
https://www.zoloft.com
[https://perma.cc/48B7-2S9A].
“WARNING:
SUICIDALITY AND ANTIDEPRESSANT DRUGS[:] ZOLOFT and other antidepressant
medicines may increase suicidal thoughts or actions in some people 24 years of age and
younger, especially within the first few months of treatment or when the dose is changed.
Watch for these changes and call your healthcare provider right away if you notice new or
sudden changes in mood, behavior, actions, thoughts, or feelings, especially if severe. Pay
particular attention to such changes when ZOLOFT is started or when the dose is changed.”
(emphasis in original); Id.; see also Sertraline, supra note 267 (Illustrating the boxed warning which reads, “Antidepressants increased the risk of suicidal thoughts and behavior in
pediatric and young adult patients in short-term studies; consider risk prior to prescribing.
Short-term studies did not show an increased risk in patients >24 years and showed a decreased risk in patients ≥65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1 to 2 months of therapy or
during periods of dosage adjustments (increases or decreases).”).
274. Nat’l
All.
on
Mental
Illness,
Sertraline
(Zoloft),
NAMI,
https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Typesof-Medication/Sertraline-(Zoloft) [https://perma.cc/8ASJ-PH5D] (“In short-term studies,
antidepressants increased the risk of suicidality in children, adolescents, and young adults
when compared to placebo.”).
275. See supra text accompanying notes 165-76.
276. See Zoloft.com Black Box Warning, supra note 273.
277. Sertraline for Premature Ejaculation, supra note 15.
278. Id.
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“Sex,”279 the user is welcomed to a page playfully headed “Enjoy the
ride.”280 There, the risk of suicide is not immediately apparent to the user
nor contained in the initial list of serious side effects which appears on the
page.281 Indeed, the black box warning is present on the site, but only after
the user clicks an embedded link which is easily overlooked and scribed in
significantly smaller font.282 Upon clicking, the user is re-routed to the bottom of the page where he is then alerted to risk of suicide when taking this
medication.283
Should this platform be subject to the regulations to which pharmaceutical manufacturers are subject, it is unlikely that this would satisfy the
FDA’s “fair balance” provision and the other rules that are slowly coming
into place for internet advertising.284 This is because, here, there is a focus
on the medication’s benefits and a downplaying of significant risk. In this
context, a patient diagnoses himself with premature ejaculation and, upon
entering the page for Sertraline, sees the fun “enjoy the ride” heading and a
suggestive cactus ad. Just as the FDA and expert commentators have voiced
concerns about graphics and imagery in traditional DTCA, be it in broadcast or print, which detract from the risks of the medication, this should be a
concern here as well.285 With Sertraline in particular, the fact that the black
box warning regarding the risk of suicide is not immediately apparent is
especially troubling. This is because the target demographic for this medication, which includes Millennials and members of Generation Z, encompasses those who are likely to be susceptible to suicidal ideation.286 This is
also a demographic that is unlikely to have visited a physician in person for
a full wellness screening, as studies have shown that individuals in this age
range are less likely to have a primary care physician.287
In this impersonal online format, facilitated by asynchronous telemedicine and largely dependent on patient questionnaires, not only is the opportunity for an in-person, physical screening lost, but other important patient
279. Telehealth for a Healthy, Handsome You, supra note 94.
280. Sertraline for Premature Ejaculation, supra note 15.
281. Id. “Some side effects can be serious. If you experience any of the following
symptoms call your doctor immediately: seizures, abnormal bleeding or bruising, agitation,
hallucinations, fever, sweating, confusion, fast heartbeat, shivering, severe muscle stiffness
or twitching, loss of coordination, nausea, vomiting, or diarrhea, rash, hives, swelling or
difficulty breathing.” Id.
282. Id.
283. Sertraline for Premature Ejaculation, supra note 15.
284. GUIDANCE FOR INDUSTRY, supra note 171.
285. Klara, supra note 60, at 656.
286. See supra text accompanying notes 268-73.
287. See Gagne & Helm, supra note 9. “Only 45% of 18-to-29-year-olds even have a
primary-care physician, according to a poll from the Kaiser Family Foundation, often due to
lack of access or health insurance.” Id.
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touchpoints are foregone, as well.288 For example, when a patient comes
into a physician’s office for an in-person appointment, the patient has the
opportunity to interact with several individuals—from the receptionist, to
the medical assistant, to the physician herself—all of whom have individual
opportunities to gauge a patient’s mental state and general demeanor. 289
These observations can be helpful in making an informed decision about
what medication is right for a patient based on his or her individual characteristics.290 This additional touchpoint of evaluation is lost in the DTC
online format and further illustrates why it is crucial that important risk
information be prominently displayed and not downplayed by DTC telemedicine websites.
Similar concerns arise when considering websites like Kick, which
prominently promote medications like beta blockers for off-label uses like
performance anxiety.291 Beta blockers are medications which are typically
used, and FDA-approved, to treat cardiac conditions such as high blood
pressure and certain cardiac arrythmias. 292 While beta blockers like Propranolol, also known as Inderal, are regularly prescribed off-label by physicians for anxiety and panic disorders,293 such medications come with risks
of side effects including, but not limited to, irregular heartbeat (arrythmia),
low heart rate (bradycardia), low blood pressure (hypotension), worsening
of existing congestive heart failure, and dizziness. 294
Kick targets users with sleep and performance anxiety issues, welcoming them to the website’s home page with a statement that reads: “Insider’s
Edge To The Best You[:] Prescription-strength treatments & performance
psychology for restorative sleep & confident presentations.”295 A user can
then click one of the buttons below the statement to begin an asynchronous,
online visit with a provider or can further browse the website to find “Kick
Guides To Living Confidently,” which address conditions and medica-

288. See Defino, supra note 4.
289. Id.
290. Id.
291. Feeling Anxious, supra note 7; see also Brown & De Vynck, supra note 6.
292. Mayo Clinic Staff, Beta Blockers, M AYO CLINIC (Aug. 16, 2019),
https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/betablockers/art-20044522 [https://perma.cc/7PQF-7HDS].
293. Drugs
&
Diseases:
Propranolol,
M EDSCAPE,
https://reference.medscape.com/drug/inderal-inderal-la-propranolol-342364
[https://perma.cc/CQE8-Q6BJ].
294. WYETH P HARMACEUTICALS, INDERAL (PROPRANOLOL HYDROCHLORIDE)
TABLETS :
M ANUFACTURER’S
LABEL
9
(2010),
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,01768
3s008lbl.pdf [https://perma.cc/FE88-94RB].
295. Kick: Insider’s Edge to the Best You, supra note 5.

2021]

ONLINE AND OFF-L ABEL

195

tions.296 The first of those guides listed is entitled “Feeling Anxious? Propranolol Can Calm Your Body And Ease Your Nerves” and the prominent,
introductory information therein explains how this medication, a beta
blocker, is used by some of the “world’s top performers, speakers, and
business professionals,” including pop star Katy Perry. 297 The guide goes
on to explain more about the biological mechanism of performance anxiety
and how beta blockers, specifically Propranolol, can help overcome the
symptoms of this condition.298 A section of the guide compares beta blockers to traditional anti-anxiety medications, like Xanax and Valium, and explains how beta blockers work for reducing symptoms of performance anxiety, going on to narrate the experience of well-known performers and
speakers.299 The guide even provides statistics about the very high percentage of musicians that have used beta blockers for anxiety and how effective
these musicians felt this treatment to be.300
This guide is ostensibly an elaborate DTCA for this medication. While
it is not conveyed in a traditional DTCA broadcast or print format, it is essentially an online pamphlet. It is hard to deny that page header taglines like
“Feel The Fear And Do It Anyway: Unblock Potential With Propranolol”301
are not akin to slogans or creative phraseology that one would encounter
when viewing a television commercial or see in a magazine advertisement
made by a pharmaceutical company. However, such a pharmaceutical company would likely violate FDA guidelines in such blatant promotion of an
FDA-approved medication for an unapproved use.302 However, Kick does
include a page in this guide that provides information about side effects and
which patients should avoid taking this medication,303 as well as a page
about off-label uses in general.304 This is important information that is easily accessible to the user. Should this innovative form of DTCA be judged
296. Kick Guides to Living Confidently, KICK, https://www.gokick.com/guides/
[https://perma.cc/GS4Q-Q3FQ].
297. Feeling Anxious, supra note 7.
298. Id.
299. Propranolol: What it Does and What it Doesn’t Do, KICK,
https://www.gokick.com/guides/anxiety/propranolol/#propranolol-what-it-does
[https://perma.cc/9HG8-W6EU].
300. Id.
301. Feel the Fear and Do It Anyway: Unblock Potential with Propranolol, K ICK,
https://www.gokick.com/guides/anxiety/propranolol/#feel-the-fear-do-it-anywaypropranolol [https://perma.cc/WP8E-PS4Q].
302. 21 C.F.R. § 202.1(e)(6)(i) (2021).
303. Propranolol
Details:
Who
Shouldn’t
Use
It,
KICK,
https://www.gokick.com/guides/anxiety/propranolol/#propranolol-who-shouldnt-use
[https://perma.cc/5CNJ-Z62Z].
304. Katy Tripses, What’s an Off-Label Prescription?, KICK (June 13, 2019),
https://www.gokick.com/blog/beta-blockers-faq/whats-an-off-label-prescription/
[https://perma.cc/DA6F-38LQ].

196

NORTHERN ILLINOIS UNIVERSITY LAW REVIEW

[Vol. 42-1

by traditional “fair balance” standards, this method of conveying information would likely be in compliance.
There are additional similarities to traditional DTCA by pharmaceutical companies as well. The guide contains a section entitled “Propranolol
Details: How To Get It” which informs website users that they may ask
either their primary care physician or a psychiatrist about this medication
or, if they are “uncomfortable asking for medication,” to use Kick’s services.305 This is similar to the DTC broadcast advertisement that instructs
consumers to ask their doctors if this medication is right for them. However, this system provides a convenient shortcut for the non-confrontational
patient who does not want to feel that she is infringing upon the prescribing
expertise of her physician. Rather, Kick offers asynchronous telemedicine
consultations with licensed providers—albeit providers who are not employed306 by Kick307—so that the patient may avoid these uncomfortable,
in-person conversations.
Viewers of ads for beta blockers for off-label use have found this promotional practice to be problematic, as well. When the DTC telemedicine
website Hers advertised Propranolol via an Instagram post and touted its
use for performance anxiety, viewers became discontent.308 The ad, which
read, “Nervous about your big date? Propranolol can help stop your shaky
voice, sweating and racing heart beat” was perceived as both dangerous and
offensive, eliciting viewer commentary on social media about the differences between clinical anxiety and situational anxiety and lodging accusa-

305. Propranolol
Details:
How
to
Get
It,
https://www.gokick.com/guides/anxiety/propranolol/#propranolol-how-to-get-it
[https://perma.cc/9SG8-BY2F].
306. See infra discussion in Part V.
307. Kick Terms of Use, supra note 25.
Kick does not provide medical advice or care. Kick contracts
with Kick Health Medical Group, an independent, physicianowned medical group with a network of United States based
Providers who provide clinical telehealth services. Kick Health
Medical Group Providers deliver clinical services via the Kick
platform to their patients. Providers are independently contracted or employed by the Kick Health Medical Group. Providers are not contracted or employed by Kick. The Providers,
and not Kick, are responsible for the quality and appropriateness of the care they render to you. The Providers are independent of Kick and are merely using the Site as a way to
communicate with you. Any information or advice received
from a Provider comes from them alone, and not from Kick.
Id.
308. Defino, supra note 4.

KICK,
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tions about unethical drug marketing. 309 Ultimately, Hers issued an apology
via another Instagram post, but viewers remained displeased.310
Nevertheless, while some DTC telemedicine websites overtly promote
FDA-approved medications for off-label, unapproved uses, they are not
regulated in the same way that pharmaceutical companies are.311 This is so
despite the fact that the means of advertising medications to patients are
very similar to that of traditional broadcast or print DTCA done by pharmaceutical companies. However, in the DTC telemedicine context, promotion
of these off-label uses goes largely unchecked by the FDA because DTC
telemedicine companies are not subject to the same regulations.
B.

PRESCRIBING CONCERNS

In addition to the concerns about promoting medications for off-label
uses via online DTC telemedicine platforms, there are valid concerns about
prescribing via these platforms, as well. The barriers to prescription access
are less extensive than in a traditional patient-physician prescribing relationship given the online system, making obtaining medication more of a
transactional process.312 While off-label prescribing is regularly and legally
performed by physicians at their discretion, such prescribing has traditionally been done following in-person evaluations where medical practitioners
are able to make decisions based on a physical and mental assessment of
the patient after the establishment of a patient-provider relationship.313 In
the DTC telemedicine context, this practice is streamlined through patient
questionnaires and asynchronous telemedicine services which can help
avoid the aforementioned “uncomfortable conversations.”
However, these potentially uncomfortable conversations come with inperson touchpoints that are important to ensure safe, effective prescribing.314 Not only is a medical practitioner able to take essential vital signs,
including blood pressure and heart rate, necessary to determine whether
beta blocker therapy is appropriate for a patient, the practitioner is also able
to evaluate whether the anxiety symptoms the patient is feeling are truly
from anxiety.315 That is, perhaps the chest discomfort one feels during self-

309. Id.
310. Id.
311. Id.
312. Gagne & Helm, supra note 9.
313. See generally id.
314. See generally Defino, supra note 4.
315. Khetpal, supra note 18 (explaining how patients may believe that they have one,
perhaps relatively benign, condition but may actually be experiencing a more complex medical phenomenon).
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diagnosed316 panic attacks is actually a cardiac event, an underlying condition that must be closely evaluated before commencing beta blocker therapy.317 Or, perhaps the self-described anxiety is something more serious
wherein further, more intensive mental health treatment, like talk therapy, is
warranted.318
Nevertheless, as discussed in Part IV above, the DTC telemedicine
companies claim to be nothing more than platforms wherein patients can
connect with medical providers. Consequently, they claim that the patient is
not establishing a patient-provider relationship with the DTC telemedicine
companies themselves because the companies are not medical providers.
Rather, the companies partner with physicians and physicians’ groups
which are licensed to practice and prescribe in the states wherein the patients are located.319 Thus, the DTC telemedicine companies take the position that these physicians are the ones establishing the patient-provider relationship and thus assuming liability for patient care and prescribing decisions, all while working within the limited scope of the relationship permitted by the site.320 This arrangement helps the websites avoid allegations of
engagement in the corporate practice of medicine and, theoretically, shields
them from liability for allegations of physician malpractice.
However, there are serious questions as to whether this is an ethical or
fair practice.321 In the DTC telemedicine context, the patient is enticed by a
prescription drug ad produced by a company that is not formally regulated
by the FDA. Often times, the patient is able to choose the medication that
he or she wants, add it to an electronic shopping cart, and pay for it. Then,
the patient is able to “connect” with a provider through asynchronous
means, usually an online questionnaire or email correspondence. While it is
true that these providers have the final say in terms of whether or not a prescription is approved,322 it is concerning that the party potentially bearing
the most liability for the transaction—the licensed physician—is effectively
moved to the back of the process. 323

316. See Gagne & Helm, supra note 9. “‘With these services, the patient selfdiagnoses, chooses the treatment, makes the request, and I worry that the doctor might just
rubber-stamp it,’ says Steven Woloshin, director of the Center for Medicine and Media at the
Dartmouth Institute.” Id.
317. See
generally
Propranolol,
DRUGS.COM
(Oct.
1,
2020),
https://www.drugs.com/pro/propranolol.html#s-34070-3 [https://perma.cc/X28D-GPYM].
318. Gagne & Helm, supra note 9.
319. Id.
320. See generally Khetpal, supra note 18.
321. See Brown & De Vynck, supra note 6.
322. Id.; see also Gagne & Helm, supra note 9.
323. See Gagne & Helm, supra note 9.
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VII. ONLINE DIRECT-TO-CONSUMER TELEMEDICINE COMPANIES’
ATTEMPTS TO AVOID LIABILITY
While the DTC telemedicine companies do their best to avoid liability
for the acts of the physicians with whom they partner to provide medical
services,324 American health law jurisprudence suggests that these platforms
may ultimately be unable to do so. Just as these companies claim to serve as
mere intermediaries between patients and providers,325 brick-and-mortar
hospitals historically claimed that they were doing nothing more than
providing a space in which practitioners could provide care to patients and
thus could only be held liable for administrative acts, not medical acts. 326
At that time, hospitals could generally only be liable for injuries to patients
caused by unsafe premises or facilities,327 such as trip-and-fall injuries,328
but not for injuries caused by physician malpractice. Thus, hospitals enjoyed a certain amount of immunity from the acts of the medical providers
that practiced within their walls. 329 Hospitals were able to avoid liability for
the acts of physicians practicing within their facilities because the physicians were deemed mere “independent contractor[s]” 330 and no principalagent relationship existed between the hospital and physicians. 331 Thus,
given the lack of an agency relationship, courts held that hospitals could not
be liable for the physicians’ medical decisions or resultant mistakes.332
However, as medicine evolved and hospitals began offering care on a
“fee-for-service”333 basis, hospitals were viewed as more than mere facilities in which physicians could perform services, but rather as integrated
medical corporations with an overarching goal of providing the best possible patient care.334 As a result, more suits were brought against hospital
324. Id.
325. Id.
326. E.g., Jones v. City of New York, 134 N.Y.S.2d 779, 781 (Sup. Ct. 1954).
327. E.g., Charrin v. Methodist Hosp., 432 S.W.2d 572, 574-75 (Tex. Civ. App.
1968).
328. Id.
329. Id.
330. E.g., Schloendorff v. Soc’y of New York Hosp., 105 N.E. 92, 93 (N.Y. 1914).
331. Id.
332. Id.
333. Gregory T. Perkes, Medical Malpractice-Ostensible Agency and Corporate
Negligence–Hospital Liability May Be Based on Either Doctrine of Ostensible Agency or
Doctrine of Corporate Negligence, 17 ST. M ARY’S L.J. 551, 555-56 (1986).
334. See, e.g., Darling v. Charleston Cmty. Mem’l Hosp., 211 N.E.2d 253, 257 (Ill.
1965).
The conception that the hospital does not undertake to treat the
patient, does not undertake to act through its doctors and nurses, but undertakes instead simply to procure them to act upon
their own responsibility, no longer reflects the fact. Present-
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physicians, even those who were ostensibly independently contracted, as
they were found to be agents of the hospital through the principles of actual
or apparent agency.335
For example, in Scott v. SSM Healthcare St. Louis a hospital argued
that it could not be held vicariously liable for the acts of an independently
contracted radiologist that failed to recognize a severe brain infection in a
CT scan of an affected patient.336 The hospital argued that there was no
direct employment—or actual agency—relationship present between the
radiologist and the hospital because the radiologist was an independent contractor.337 In support of this argument, it noted that the radiologist’s relationship with the hospital was based upon a written contract, the radiologist
was a partner in his own professional healthcare corporation through which
he was paid, the hospital did not set the radiologist’s hours, and the hospital
did not bill patients directly for the radiologist’s services. 338
The plaintiffs, however, argued that the radiologist was an agent of the
hospital because the hospital “generally controlled, or had the right to control, the conduct of the [radiologist] in his work performed at the hospital.”339 Specifically, the plaintiffs noted, inter alia, that the contract between
the hospital and the radiologist was of infinite duration, the hospital could
terminate the contract at any time, the hospital determined the qualifications
necessary for radiologists to be employed by the hospital, and the hospital
set the prices for the radiologist’s services.340 In addition, the radiologist
was an “active member” of the hospital’s staff, the radiologist’s practice
was the exclusive provider of radiology services in the hospital, and the
hospital owned all the space and equipment wherein and with which the
radiologist practiced.341 As a result, the court found that the evidence presented was sufficient to create a jury question about whether or not the radiologist was an agent of the hospital and thus whether the hospital could
be held vicariously liable for the acts of the radiologist.342 Ultimately, an
award for the plaintiffs was affirmed.343
The DTC telemedicine platforms, claiming to be mere neutral spaces
in which patients can connect with providers to receive care, are much like

Id.

day hospitals, as their manner of operation plainly demonstrates, do far more than furnish facilities for treatment.
335.
336.
337.
338.
339.
340.
341.
342.
343.

Perkes, supra note 333, at 556.
Scott v. SSM Healthcare St. Louis, 70 S.W.3d 560 (Mo. Ct. App. 2002).
Id. at 567.
Id.
Id. at 566-67.
Scott, 70 S.W.3d at 567.
Id.
Id. at 568.
Id.

2021]

ONLINE AND OFF-L ABEL

201

the hospitals that held themselves out as mere facilities where doctors could
render services. The DTC telemedicine platforms claim to establish a “direct customer relationship”344 with the user of the platform and, in this way,
likely seek to limit their potential liability to technical malfunctions or administrative errors. This is analogous to how hospitals were initially liable
only for administrative or premises-related injuries to “users” of the hospital.345 Furthermore, much like the hospital in Scott, which claimed that it
could not be liable for the acts of the independently contracted radiologist,
these platforms expressly disclaim liability for the acts of the independent
providers with whom they partner.346
However, just as this argument did not hold up for hospitals in the
long run, it is unlikely to do so for the DTC telemedicine platforms. Just as
the radiologist in Scott was found to be under the direction and control of
the hospital, establishing an agency relationship wherein the hospital could
be held vicariously liable for the radiologist’s acts, physicians that partner
with DTC telemedicine companies could be easily viewed the same way.
Just as the radiologist in Scott held an exclusive contract with the hospital
for radiology services, some physicians’ groups may hold exclusive contracts with the DTC platforms, sometimes even sharing a common name,
e.g., Kick and Kick Health Medical Group. 347 Also, just as the radiologist
was an active member of the hospital staff, some physicians’ groups share
physical office space or overlap leadership with the DTC telemedicine
companies.348 Some DTC telemedicine companies pay physicians on an
hourly basis349 and assign them patients through the platforms’ portals via a
matching system. 350 Just as the hospital in Scott provided all the space and
equipment wherein and with which the radiologist practiced, the physicians
that partner with the DTC telemedicine companies operate strictly within
344. Hims: Terms & Conditions, supra note 25.
345. See Jones v. City of New York, 134 N.Y.S.2d 779, 781 (Sup. Ct. 1954); Charrin
v. Methodist Hosp., 432 S.W.2d 572, 574-75 (Tex. Civ. App. 1968).
346. See, e.g., Cove Terms of Use,
COVE (Mar.
23,
2020),
https://www.withcove.com/legals/terms-of-use [https://perma.cc/4XD2-S658].
347. “Kick does not provide medical advice or care. Kick contracts with Kick Health
Medical Group, an independent, physician-owned medical group with a network of United
States based Providers who provide clinical telehealth services. Kick Health Medical Group
Providers deliver clinical services via the Kick platform to their patients.” Kick Terms of
Use, supra note 25.
348. See Gagne & Helm, supra note 9 (explaining that Ro, a multifaceted direct-toconsumer telemedicine company, maintains its primary physician network through Roman
Pennsylvania Medical with whom it shares office space. Additionally, Roman Pennsylvania
Medical’s owner is Ro’s clinical director).
349. Id. (“Hims partners with an outside firm called Bailey Health, which pays physicians between $120 and $150 an hour.”).
350. Id. (explaining how a physician contracted by Hims logs into the Hims online
portal “to see which customer the system has matched him with.”).
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the parameters of the platform. Because of their contracts with and commitments to the DTC telemedicine companies, doctors effectively operate
on “islands of care” within the parameters of the companies. 351 Doctors are
unable to address secondary issues that may arise during the course of a
consultation and are generally unable to “add information to a patient’s
home medical record.”352 They are limited in terms of the scope of advice
that they may offer and in their ability to follow up with patients’ progress.
Also, as one physician commentator353 notes, “[the doctors] surely must
feel some pressure to push their employer’s [the DTC medicine website’s]
products.”354 This further illustrates the extent to which the physicians function under the control of the DTC telemedicine companies.
In summary, there are clear congruencies between hospitals’ attempts
to limit liability for the acts of “independent” physicians and those attempts
currently being made by the DTC telemedicine companies. Even if these
companies are viewed as mere facilitators of care at the present time, there
is evidence that the companies are becoming increasingly popular, particularly in light of the COVID-19 pandemic.355 They are increasingly expanding their offerings to include a broad array of testing356 and prescriptions,
and they induce patients to use their services through DTCA, just as a hospital may do through advertisements on a roadside billboard or in a local
magazine. Therefore, just as hospitals eventually came to be viewed as integrated medical corporations, it is likely that the DTC telemedicine companies will follow suit. Liability for the acts of contracted physicians will
follow, and for that reason it is important that Congress or regulatory agencies govern DTC telemedicine operations specifically. Such oversight will
ultimately help protect patients, DTC companies themselves, and help to
preserve the integrity and reputation of the medical profession.
VIII.
A.

RECOMMENDATIONS FOR REGULATION OF DIRECT-TO-CONSUMER
TELEMEDICINE WEBSITES

WHY FEDERALLY REGULATE DTC TELEMEDICINE COMPANIES?

As discussed above,357 DTC telemedicine websites have grown in
popularity over the years, particularly during the COVID-19 pandemic.
351. Khetpal, supra note 18.
352. Id.
353. Id. The author, Vishal Khetpal, was a third-year medical student when he authored this article and is currently an internal medicine physician. See VISHAL K HETPAL,
https://vishalkhetpal.com [https://perma.cc/NL9T-L6WF].
354. Khetpal, supra note 18.
355. JAIN & M EHROTRA, supra note 11.
356. Azevedo, supra note 116.
357. See supra text accompanying notes 113-17.
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These websites may, indeed, become part of the post-pandemic “new normal.” Patients, particularly those who are members of younger, tech-savvy
generations, have come to rely on these websites for fulfilment of everyday
prescription medications. Consequently, these patients may continue to
depend on this mode of healthcare delivery for monthly prescription refills
if they remain satisfied with the DTC telemedicine companies’ offerings. It
follows that, given increased reliance on electronic prescription and delivery of medication, these individuals—who statistically lacked a primary
care provider prior to turning to DTC telemedicine358—may be less likely to
visit a doctor’s office for routine screenings. For this reason, it is essential
that either Congress or a regulatory agency take appropriate measures to
protect patients as they continue to have their healthcare needs met through
this novel delivery system.
Regulation of DTC telemedicine is in the best interest of the medical
profession, as well. Doctors are afforded broad latitude to prescribe as they
see fit, even when it comes to medications for off-label uses.359 If adverse
events transpire as a result of injudicious online drug promotion and subsequent DTC prescribing, physicians may be viewed as lacking in their abilities to make proper decisions about patient care. This could undermine public trust in the medical profession and lead to imposition of legal liability on
medical practitioners. If Congress or a regulatory agency does not step in
on the federal level, common law will likely fill the gaps as lawsuits against
providers, or the platforms themselves, come about. Judicial resolution of
suits in varied jurisdictions may lend itself to a lack of rule uniformity and
confusion for all parties involved. Therefore, regulation of DTC telemedicine companies at the federal level should be strongly considered.
B.

SUBJECT DTC TELEMEDICINE COMPANIES TO SIMILAR REGULATION AS
THAT TO WHICH PHARMACEUTICAL COMPANIES ARE SUBJECT

As discussed above,360 the DTC telemedicine platforms are engaging
in an elaborate form of DTCA on a regular basis which is much like the
DTCA long utilized by pharmaceutical manufacturers. Nevertheless, while
pharmaceutical manufacturers’ DTC advertisements are subject to an elaborate composition of legislation and agency regulations, online telemedicine
DTCA is left largely unchecked.361 The DTCA method employed by DTC
telemedicine companies ostensibly poses more, or at least comparable, risks
358. See Gagne & Helm, supra note 9.
359. Cortez, supra note 221, at 124. “[P]hysicians may prescribe products independently from, and occasionally in defiance of, the approved labeling.” (internal quotations
omitted). Id.
360. See supra text accompanying notes 262-310.
361. See supra text accompanying notes 262-65.
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to patient welfare than those posed through DTCA by pharmaceutical manufacturers. This is because DTC telemedicine companies’ patients have
one-stop-shop access to medications, including those advertised and prescribed for off-label, non-FDA approved uses, without visiting a doctor in
person or undergoing a physical screening.362 Furthermore, these websites
frequently utilize exclusively asynchronous telemedicine technology wherein the patient’s interaction with the physician is limited to questionnaires
and email correspondence.363
The rules for DTCA by pharmaceutical companies were put in place to
protect patients while consequently allowing them to be informed participants in their care.364 Such rules are particularly crucial in the realm of
drugs prescribed for off-label uses. Therefore, it seems natural that DTC
telemedicine companies should be subject to FDA rules surrounding pharmaceutical promotion, particularly those rules which proscribe ads that are
“false, lacking in fair balance, or otherwise misleading.”365 Given the
streamlined nature of prescription access through DTC telemedicine websites, the frequent use of mere questionnaires to evaluate patients’ health
histories, and the limited scope in which the physicians with whom the
DTC telemedicine companies can operate, it is crucial that the United States
government make every effort to ensure that patients are well informed
about the medications advertised to them. Since a regulatory framework of
this nature is already in place for pharmaceutical companies, it is logical to
bring DTC telemedicine companies, which employ similar drug promotion
tactics, under the umbrella of this governance.
Furthermore, some experts speculate that as DTC telemedicine platforms continue to proliferate and thrive, they will ultimately be acquired by
pharmaceutical manufacturers.366 In this event, FDA rules applicable to
pharmaceutical companies may govern by default, in some respects. However, since pharmaceutical companies have not historically transacted business nor promoted medications in this one-stop-shop, DTC manner via the
internet, existing guidelines will likely need to be enhanced or adjusted to
better reflect this mode of healthcare delivery. Therefore, regardless of
whether DTC telemedicine companies remain autonomous startups or if
they are acquired by pharmaceutical companies, the present time is not too
soon to consider federal governance of this healthcare model.
362. See supra text accompanying notes 311-13.
363. See supra text accompanying notes 320-22.
364. See supra text accompanying notes 143-48.
365. 21 C.F.R. 202.1(e)(6) (2021).
366. See generally Zoë LaRock, Pharma Could Become More Active in Direct-toConsumer Drug Delivery in 2020, BUS. INSIDER (Jan. 2, 2020, 8:47 AM),
https://www.businessinsider.com/pharma-could-set-sights-on-direct-to-consumer-drugdelivery-2020-1 [https://perma.cc/JPS5-KU7A].

2021]

C.

ONLINE AND OFF-L ABEL

205

LOOK TO ONLINE PHARMACY LEGISLATION FOR ADDITIONAL GUIDANCE
TO AID IN MODEL LEGISLATION

In addition to examining existing regulations governing pharmaceutical company operations, lawmakers may look to federal governance of
online pharmacies for guidance on how to regulate DTC telemedicine companies. As discussed above,367 the Ryan Haight Act was enacted in response
to grave concerns regarding patient safety in the realm of online prescribing. The Act was promulgated with “rogue” pharmacies in mind, as well as
online pharmacies that remotely prescribe through a questionnaire-based
system. 368 While the Act ostensibly fell short by failing to regulate noncontrolled substances,369 its primary, substantive provisions may provide a
framework for legislation of DTC telemedicine companies. This is because
DTC telemedicine companies, like some online pharmacies, similarly rely
on online prescribing with limited physician involvement.
For example, model legislation could require something similar, but
not identical to, the Ryan Haight Act’s in-person evaluation requirement.370
However, such legislation would need to be tailored so as to not completely
undermine the primary purpose of DTC telemedicine, namely the convenience of on-demand care. Thus, perhaps such a requirement in this context
could entail the patient certifying that: (1) he or she has undergone a physical examination with a licensed practitioner within the previous two years,
or another appropriate time frame, and (2) that the physical examination
revealed nothing that would undermine the safety or efficacy of the medication being remotely prescribed. Such a requirement would arm remotely
prescribing physicians with information regarding a patient’s physical condition and potential comorbidities, rather than merely relying on selfreported vitals. The requirement would be particularly useful where medications prescribed online carry potentially harmful side effects, including
beta blockers and antidepressants prescribed for off-label uses. The legislation could also encourage patients to coordinate DTC telemedicine services
with an in-person, primary care physician for follow-up and monitoring so
as to ensure that the medication is appropriate and that any adverse side
effects are promptly recognized and addressed.
The Ryan Haight Act’s monthly quantity reporting requirement371 may
also serve as a useful model. Just as the Ryan Haight Act requires online
pharmacies to report the quantity of controlled substances dispensed on a
monthly basis unless the amounts dispensed fall below certain designated
367.
368.
369.
370.
371.

See supra text accompanying notes 193-99.
See supra text accompanying notes 194-99.
See supra text accompanying notes 210-13.
See supra text accompanying note 200.
See supra text accompanying note 202.

206

NORTHERN ILLINOIS UNIVERSITY LAW REVIEW

[Vol. 42-1

thresholds, perhaps DTC telemedicine companies which frequently facilitate prescriptions for off-label use medications should be required to report
prescriptions sold at a certain frequency. A specific rule for reporting may
depend on further analytics including, but not limited to, the specific medications sold, potentiality for adverse side effects, reports of adverse reactions, and the frequency at which such a medication is prescribed in an inperson, traditional healthcare setting. Consequently, an ancillary benefit of
legislation of this nature is that it may provide an avenue to expansion of
online pharmacy governance into the realm of non-controlled substances.
IX. CONCLUSION
Notwithstanding the foregoing discussion, given tangential influences
from regulatory agencies including the FDA, FTC, and DEA, as well as
state medical boards, it has been argued that a regulatory gap does not exist
in the area of DTC telemedicine.372 Commentators contend, rather, that this
is a heavily regulated space.373 Nevertheless, the fact remains that there is
no specific legislation or agency regulations governing DTC telemedicine
company operations. The tangential influences from several entities create a
proverbial “too many cooks in the kitchen” situation which increases the
likelihood that important issues, including patient safety and confidence in
physician prescribing practices, will fall through the cracks. In this event,
common law is likely to fill these cracks on a case-by-case basis with jurisdiction-specific rulings that carry the potential to create confusion and inconsistency on a large-scale basis. As DTC telemedicine companies continue to gain popularity in a post-pandemic environment, it is essential that
lawmakers act at the federal level in order to protect patients and preserve
the integrity of the medical profession.
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HCLT Podcast, supra note 104.
Id.
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APPENDIX A
Table of Acronyms
AMA – American Medical Association
CMS – Centers for Medicare and Medicaid Services
CSA – Controlled Substances Act
DEA – Drug Enforcement Administration
DTC – Direct-to-consumer
DTCA – Direct-to-consumer advertising
FCA – False Claims Act
FDA – U.S. Food and Drug Administration
FDCA – Food, Drug, and Cosmetic Act
FTC – Federal Trade Commission
OPDP – Office of Prescription Drug Promotion
OTC – Over-the-counter
PhRMA – Pharmaceutical Research and Manufacturers of America
SSRI – Selective Serotonin Reuptake Inhibitor
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